Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee; Pei-Shan Wu; Han-Chieh Lin

doi:10.3350/cmh.2022.0237

Articles

Page Path

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee^1,2

, Pei-Shan Wu^1,2,3, Han-Chieh Lin^1,2

Clinical and Molecular Hepatology 2023;29(1):77-98.
Published online: October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

¹Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

²Department of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan

³Endoscopy Center for Diagnosis and Treatment, Taipei Veterans General Hospital, Taipei, Taiwan

Corresponding author : Kuei-Chuan Lee Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 11217, Taiwan Tel: +886 2 2871 2121, Fax: +886 2 2873 9318, E-mail: kclee2@vghtpe.gov.tw

Han-Chieh Lin Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 11217, Taiwan Tel: +886 2 2871 2121, Fax: +886 2 2873 9318, E-mail: hclin@vghtpe.gov.tw

Editor: Dae Won Jun, Hanyang University College of Medicine, Korea

• Received: August 4, 2022 • Revised: October 1, 2022 • Accepted: October 11, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

41,539 Views
943 Download
214 Web of Science
221 Crossref
228 Scopus

prev next

Full Article

Download PDF

ABSTRACT
INTRODUCTION
PATHOGENESIS OF NASH
DEVELOPMENT OF NASH FIBROSIS
ORGAN-ORGAN INTERACTION LEADING TO PROGRESSION OF NASH AND ITS FIBROSIS
PROGRESSION OF NASH TO HCC
TREATMENT FOR NASH
PERSPECTIVES
ACKNOWLEDGMENTS
FOOTNOTES
Abbreviations
REFERENCES

ABSTRACT

The initial presentation of non-alcoholic steatohepatitis (NASH) is hepatic steatosis. The dysfunction of lipid metabolism within hepatocytes caused by genetic factors, diet, and insulin resistance causes lipid accumulation. Lipotoxicity, oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum stress would further contribute to hepatocyte injury and death, leading to inflammation and immune dysfunction in the liver. During the healing process, the accumulation of an excessive amount of fibrosis might occur while healing. During the development of NASH and liver fibrosis, the gut-liver axis, adipose-liver axis, and renin-angiotensin system (RAS) may be dysregulated and impaired. Translocation of bacteria or its end-products entering the liver could activate hepatocytes, Kupffer cells, and hepatic stellate cells, exacerbating hepatic steatosis, inflammation, and fibrosis. Bile acids regulate glucose and lipid metabolism through Farnesoid X receptors in the liver and intestine. Increased adipose tissue-derived non-esterified fatty acids would aggravate hepatic steatosis. Increased leptin also plays a role in hepatic fibrogenesis, and decreased adiponectin may contribute to hepatic insulin resistance. Moreover, dysregulation of peroxisome proliferator-activated receptors in the liver, adipose, and muscle tissues may impair lipid metabolism. In addition, the RAS may contribute to hepatic fatty acid metabolism, inflammation, and fibrosis. The treatment includes lifestyle modification, pharmacological therapy, and non-pharmacological therapy. Currently, weight reduction by lifestyle modification or surgery is the most effective therapy. However, vitamin E, pioglitazone, and obeticholic acid have also been suggested. In this review, we will introduce some new clinical trials and experimental therapies for the treatment of NASH and related fibrosis.
Keywords: Liver fibrosis; Steatohepatitis; Fatty liver

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent type of liver disease worldwide. NAFLD is a wide hepatic spectrum, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which leads to progressive fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [1]. Fat accumulation in hepatocytes sensitizes hepatocytes to injury, leading to cell death, inflammatory cells recruitment, and activation of hepatic stellate cells (HSCs) [2]. The pathogenesis of NASH and its fibrosis has been broadly investigated for decades, and the development and progression of NASH and liver fibrosis involves complex interplay of numerous determinants. Understanding of the pathogenesis of NASH and liver fibrosis is important for the diagnosis and development of treatment. Although new drugs have been developed to target liver inflammation and fibrosis in NASH, only a minority of patients achieve treatment response [3]. Thus, there is still an urgent need to develop new therapeutic agents for NASH.

PATHOGENESIS OF NASH

Development of hepatic steatosis

Diet

High-fat diet can result in hepatic steatosis in humans. Liver fat increased by 35% in overweight non-diabetic women after a 2-week isocaloric high-fat diet (56% total energy from fat) [4]. A 3 days of high-fat, high-energy diet in healthy males resulted in major increases in plasma triglyceride (TG) and non-esterified fatty acid (NEFA) concentrations and hepatic TG [5]. A single energy-dense, high-fat meal induced net lipid accumulation in the liver of healthy subjects [6]. Moreover, palm oil administration in lean, healthy individuals decreased whole-body, hepatic, and adipose tissue insulin sensitivity by 25%, 15%, and 34%, respectively; increased hepatic TG and ATP content by 35% and 16%, respectively; increased hepatic gluconeogenesis by 70%; and decreased glycogenolysis by 20% [7]. In young Finnish adults, serum fatty acid saturation independently predicted the 10-year risk for fatty liver and omega-6 (ω6) fatty acids inversely associated with fatty liver [8]. A long-term hypercaloric diet, rich in saturated fatty acid (SFA), showed a marked increase in liver fat content by 50%, and ω6 polyunsaturated fatty acids (PUFAs) decreased fatty liver in overweight humans [9]. However, a lipidomic analysis showed that the n-6:n-3 free fatty acids (FFAs) ratio increased in NASH livers as compared to normal livers [10]. These studies suggested that hypercaloric diet, especially high in fat and sugar, contribute to the development of fatty liver; SFA and fructose are more detrimental, but the role of the ω6/ω3 fat ratio also remains controversial.

Physical inactivity

NAFLD patients have low level of physical activity compared to normal controls. Gerber et al. [11] showed that the average physical activity, counted by an accelerometer of NAFLD subjects, was about 28.7 counts/minute/day. In an Asian group, prolonged sitting time and decreased physical activity level were found to positively associated with the prevalence of NAFLD, and these associations were also observed in subjects with body mass index <23 kg/m² [12]. However, the detail mechanism of sedentary behavior or low physical activity leading to fatty liver remains unclear. Lower expenditure of energy or lower skeletal muscle mass might explain a possible connection between sedentary behavior and NAFLD.

Insulin resistance

NAFLD is strongly associated with reduced whole body insulin sensitivity, as well as increased hepatic and adipose tissue insulin resistance [13,14]. Insulin resistance can lead to hepatic fat accumulation by increasing FFA delivery to the liver, increasing de novo lipogenesis (DNL), and decreasing hepatic fatty acid oxidation. A landmark study performed by Donnelly et al. [15] demonstrated that in NAFLD patients, about 59% liver triacylglycerol arose from NEFAs, 26.1% from DNL, and 14.9% from the diet, and that the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state without diurnal variation [15]. Insulin resistance can impair the insulin suppression of lipolysis of peripheral adipose tissues, leading to increased delivery of FFAs to the liver [16]. Insulin can stimulate sterol receptor binding protein 1-c (SREBP1c), increasing DNL in the liver [17,18]. Chronic hyperinsulinemia results in the cytoplasmic localization and inactivation of Foxa2 phosphorylation in hepatocytes, thereby promoting lipid accumulation and insulin resistance in the liver [19].

Genetic factors

There are several gene variants associated with NAFLD and NASH. The first fatty liver gene identified by Romeo et al. [20] is patatin-like phospholipase domain-containing 3 (PNPLA3). The single nucleotide polymorphism (SNP) rs738409 causes the missense sequence variation I148M, impairing the phospholipase activity and increasing hepatic fat content [20]. Glucokinase regulatory protein (GCKR) can regulate hepatic glucose uptake and hepatic glucokinase activity, and the intronic SNP rs780094 is associated with hepatic lipid content [21,22]. The SNP rs1260326 (C>T; P446L), GCKRP446L can decrease the inhibition of glucokinase, leading to increased glycolytic flux to hepatocytes, then hepatic steatosis [23]. The rs58542926 (G>A; E167K) variant, transmembrane 6 superfamily 2 (TM6SF2), was associated with increased hepatic TG content [24]. The inhibition of TM6SF2 in hepatocytes reduced the secretion of very-low-density lipoprotein (VLDL), leading to the retention of TGs [25]. In a Taiwanese population, a variant in the immunity-related GTPase M (IRGM) gene (rs10065172 TT genotype) independently increased the odds ratio of NAFLD by 2.04 by altering hepatic lipid metabolism through the autophagy pathway [26]. Similarly, the IRGM rs10065172 variant increased the risk for hepatic steatosis, but not for liver inflammation or fibrosis, in obese Italian children [27]. Recently, the mechanisms underlying metabolic and genetic components of NAFLD were found to be fundamentally different in patients. The metabolic component is characterized by hepatic oversupply of sugars and lipids, while the genetic component is characterized by impaired hepatic mitochondrial function, reducing the liver’s ability to metabolize these substrates [28].

Epigenetic factor

Using an epigenome-wide association study in peripheral blood cells, 22 CpGs were found to be associated with hepatic fat in European participants; 19 CpGs were annotated to 18 unique genes upregulated in the liver, including DHCR24, SLC43A1, CPT1A, SREBF1, SC4MOL, and SLC9A3R1 [29]. Some alternations of intrahepatic microRNA (miRNA) have been associated with hepatic steatosis. The serum levels of miR-122 and miR-192 were upregulated in patients with simple steatosis compared to normal controls [30]. The administration of exosomes transfected with obesity-associated miRNA induced hepatic steatosis in lean mice [31]. miR-122 inhibition in normal mice caused increased hepatic fatty acid oxidation [32]. Decreased miR-122-5p in the human liver was associated with impaired fatty acid usage [33]. However, the deletion of mouse miR-122 resulted in hepatosteatosis, inflammation, and the development of tumors [34]. The expression of miR-34 was elevated in NAFLD patients. miR-34a down-regulated autophagy in hepatocytes by targeting ATG4B and Rab-8B and suppressed mitochondrial biogenesis, leading to lipids accumulation in the liver [35].

Lipotoxicity

Endoplasmic reticulum (ER) stress

The ER is responsible for protein folding, and the accumulation of misfolded or unfolded proteins leads to stress and the activation of the unfolded protein response (UPR) [36]. There are three sensor proteins that activate UPR, namely the inositol-requiring enzyme 1 (IRE1), the protein kinase R (doublestranded RNA-activated protein kinase)-like ER kinases (PERK), and the activating transcription factor 6. The UPR can cause inflammation, inflammasome activation, and death of hepatocytes [37]. Patients with NASH have been shown to be specifically associated with failure to generate X-box-binding protein 1 (XBP-1) protein and activation of JNK [38]. Palmitate can induce the ER stress response, as demonstrated by the increase in C/EBP homologous protein (CHOP) expression, eIF2-alpha phosphorylation, XBP-1 splicing, and JNK activation with increased expression of the BH3-only proteins PUMA and Bim [39]. Perturbation of membrane lipid composition could promote IRE1 and PERK activation, suggesting a lipid-sensing mechanism for ER sensors to activate the UPR [40]. NFATc1 drives hepatocyte damage and inflammation through activation of the PERK-CHOP [41].

Mitochondrial dysfunction

Increased hepatic fat would increase hepatic fat oxidation with increased mitochondrial respiration [42,43]; however, decreased efficiency of respiratory chain complexes with greater mitochondrial uncoupling and leaking activity was found in patients with NAFLD [43,44]. Chronic mitochondrial dysfunction in the state of lipid overload led to excessive leakage of electrons from mitochondrial respiratory complexes, leading to oxidative stress [45]. Voltage-dependent anion channel acted as an early sensor of lipid toxicity, and its glycogen synthase kinase 3-mediated phosphorylation status controlled outer mitochondrial membrane permeabilization in hepatocytes with fat accumulation [46]. Exposure of hepatocytes to saturated FFAs caused mitochondrial depolarization, cytochrome c release, and increased ROS production [47]. Furthermore, intake of SFAs can affect the composition of mitochondrial membrane and decrease the efficiency of the respiratory transport chain, resulting in increased oxidative stress and chronic liver injury [48]. Peng et al. [49] found that hepatic cardiolipin and ubiquinone accumulated in NAFL and the levels of acylcarnitine increased with NASH, and proposed that increased levels of cardiolipin and ubiquinone may help to preserve mitochondrial function in early NAFLD; however, mitochondrial function eventually fails with the progression of NASH, leading to increased acylcarnitine. Moreover, SFAs increased ceramide synthesis in hepatocytes [50], which correlated with hepatocyte death via mitochondrial failure [51,52].

Lysosomal dysfunction

It has been shown that hepatic activity of lysosomal acid lipase and lysosomal acidification, which are markers of lysosomal dysfunction, are decreased in patients with NAFLD [53,54]. Both steatotic- and asparagine-treated hepatocytes showed reduced lysosomal acidity and retention of lysosomal calcium [55]. FFAs resulted in Bax translocation to lysosomes and lysosomal destabilization with the release of cathepsin B into the cytosol, leading to nuclear factor kappa B-dependent tumor necrosis factor alpha expression and apoptosis [56,57]. Lysosomal permeabilization and cathepsin B redistribution into the cytoplasm occurred several hours prior to mitochondrial dysfunction [47]. Furthermore, autophagy could sequester intracellular proteins and organelles in double-membrane vesicles (autophagosomes) to lysosomes for degradation. Autophagy in the regulation of intracellular lipid stores is called macrolipophagy [58]. Toxic fatty acids inhibited autophagic flux with reduction in lipophagy, which could lead to cell injury [59].

Oxidative stress and apoptosis

The main mechanisms of fatty acid-induced damage are oxidative stress and increased pro-inflammatory cytokines [2]. These insults from the ER stress, mitochondrial dysfunction, and oxidative stress in the hepatocytes after lipid accumulation could cause lipotoxicity, leading to apoptosis, necroptotis, or pyrotosis [60,61]. Saturated FFAs can also induce apoptosis through intrinsic and extrinsic pathways. The oxidative stress and ER stress induced by accumulated fatty acids can activate CHOP and JNK, and then upregulate Bim, Bax, and Bak, leading to the release of cytochrome C and caspase 9-associated apoptosis. In addition, death receptor pathways, including TRAIL/TRAIL receptor, tumor necrosis factor-α (TNFα)/TNF receptor 1 (TNFR1), and Fas ligand/Fas, were noted to be activated by FFAs on hepatocytes [62].

DEVELOPMENT OF NASH FIBROSIS

Liver fibrosis is the most important risk factor for liver cancer in patients with NAFLD and decompensated cirrhosis [63]. In patients with NAFLD, age and comorbidities, such as hypertension, overweighted, and diabetes mellitus, are risk factors for progression of fibrosis [64-66].

Lipotoxic damage in hepatocytes would release cytokines and chemokines, and then activate innate and adaptive immune cells, including macrophages, dendritic cells, lymphocytes, and neutrophils, leading to an inflammation cascade [67]. Damaged hepatocytes also release extracellular vesicles containing exosomes, microparticles, and apoptotic bodies. These vesicles, containing signaling proteins, sonic hedgehog (Hh), lipids, mRNAs, non-coding RNAs, and DNA, can induce inflammation, fibrosis by activating non-parenchymal cells, and recruitment of immune cells [68,69]. Meanwhile, apoptotic bodies can also be engulfed by stellate cells and subsequently induce HSC activation, which increases the expression of α–smooth muscle actin, transforming growth factor β (TGFβ), and collagen type I [70]. Moreover, the Hh pathway was not only activated in hepatocytes, leading to macrophage recruitment and progression of inflammation [71], but it also induced epithelial-to-mesenchymal transitions in ductular-type progenitors [72]. Cholangiocytes and natural killer T cells also activated Hh-osteopontin pathway and promoted fibrogenic responses of HSCs in NASH [73,74].

Toxic fatty acids were able to directly affect Kupffer cells (KCs) and HSCs, which may contribute to the activation of inflammation and fibrosis. Palmitic acids activated toll-like receptor (TLR) 2 and TLR4 in macrophages with the induction of inflammatory signaling [75]. KCs exhibited a pro-inflammatory response with elevated levels of TNFα, interleukin (IL)-6, and IL-1β after treatment by palmitic acids [75]. Palmitate induced ER stress and actin stress fiber formation in activated HSCs. Oleate induced the inflammatory signal and decreased cytoskeleton proteins in activated HSCs [76]. Free cholesterol was increased in patients with NAFLD, and the accumulation of free cholesterol in HSCs sensitized these cells to TGFβ-induced activation, leading to exaggerated liver fibrosis in NASH [10,77].

Insulin exerts profibrogenic activity. Insulin itself induces HSC mitogenesis and collagen synthesis [78,79]. However, insulin enhances the expression of smooth muscle actin-α in quiescent, but not in activated HSC through the PI3K/Akt-p70S6K pathway [80].

HSCs express PNPLA3 and membrane-bound O-acyltransferase domain-containing protein 7 (MBOAT7) [81,82]. Increased PNPLA3 expression reduces lipid droplet content in HSCs [81]. Autophagy promotes loss of lipids in HSCs to provide energy for HSC activation [83]. PNPLA3I148M can interfere with retinol production and release of HSCs by affecting the retinyl-palmitate lipase activity, which may promote fibrosis progression [81]. The MBOAT7 rs641738 T allele was associated with lower protein expression in the liver, and changes in plasma phosphatidylinositol species were consistent with decreased MBOAT7 function [82]. Hepatocyte-specific knockout of Mboat7 increased hepatic fibrosis with increased total lysophosphatidylinositol levels [84], which could promote the initiation of HSC activation by stimulating G-protein receptor 55 [85]. TM6SF2E167K was associated with higher risk of advanced fibrosis in NAFLD patients [86]. Furthermore, the gene encoding for the hepatic hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) regulated hepatic phospholipids and chronic liver injury in NAFLD patients [87-89]. The HSD17B13 rs72613567 variant led to the loss of enzyme function, contributing to reduced inflammation and fibrosis in the liver [88]. In addition, the HSD17B13 rs72613567 variant affected retinol metabolism by reducing the activity of retinyl-palmitate lipase, mediating antifibrotic and anti-inflammation effects [90].

Hypomethylation or hypermethylation of genes involved in the wound-healing process in NAFLD could be used to distinguish between patients with mild fibrosis from those with severe fibrosis in NAFLD. Hypermethylation at specific CpGs within TGFβ1 and PDGF, and hypomethylation at specific CpGs within peroxisome proliferator-activated receptor (PPAR) α and PPARδ in patients with mild fibrosis, were found [91].

ORGAN-ORGAN INTERACTION LEADING TO PROGRESSION OF NASH AND ITS FIBROSIS

Gut-liver axis

Compared with healthy adults, patients with NAFLD had a higher proportion of Firmicutes in the intestine, and the relative numbers of Bacteroidetes, Enterobacteriaceae, and Ruminococcaceae families were reduced [92,93]. Dysbiosis may disturb gut barriers, and bacteria and its products from the gut, such as endotoxin and cytokines, that promote inflammation, could enter the liver through blood, and activate the immune response in the liver and increase liver inflammation and fibrosis [94,95]. Compared with healthy people, patients with NAFLD had dysbiosis and increased intestinal permeability, and patients with steatohepatitis were observed to have endotoxemia [96,97]. Low-dose endotoxin stimulations were able to produce steatohepatitis in obese mice [98]. Conversely, blocking the signals caused by the immune system to recognize bacteria and its products effectively improved the severity of steatohepatitis [99,100]. Bacterial products and translocated lipopolysaccharide stimulated the hepatic innate immune system through TLR4 signaling, predominantly on HSCs and KCs [101]. TLR4-mediated stimulation of HSCs led to HSC activation and KC activation [102]. In turn, KCs produced TGFβ, stimulating fibrogenesis, and the proinflammatory cytokines, propagating hepatic inflammation. KCs also produced reactive oxygen species, leading to the generation of other reactive nitrogen species and local tissue damage [102,103]. Mice fed with high-fat diet for only 1 week underwent a diet-induced dysbiosis, driving the damage on gut vascular barrier and causing bacterial translocation into the liver [104]. However, only 42.1% of patients with steatohepatitis had elevated endotoxin levels [105] and 39.1% of fatty liver patients had increased intestinal permeability [106]. Therefore, bacterial translocation due to gut barrier impairment may play a partial role in the development and progression of NAFLD and its fibrosis.

Some metabolites in the blood and feces have been found to rely on bacterial synthesis, including choline and choline-related metabolites, bile acids, short-chain fatty acids (SCFAs), and ethanol, which may contribute to the pathogenesis of fatty liver. In animal experiments, the gut microbiota of mice fed with high-fat diet could convert choline into trimethylamine, reduce the bioavailability of choline, and produce a phenomenon similar to choline-deficient diet, leading to decreased excretion of VLDL from liver cells and increased liver fat accumulation [107]. Intestinal dysbiosis would increase the deoxycholic acid:chenodeoxycholic acid ratio, reduce the activation of farnesoid X receptor (FXR) signaling in the liver, reduce insulin sensitivity, increase glycogen and lipogenesis, and reduce fatty acid oxidation in the liver [108]. At the same time, gut dysbiosis also inhibited FXR, reduced the secretion of fibroblast growth factor (FGF) 15/19, leading to fatty liver [109]. SCFAs, such as acetate, propionate, and butyrate, are the products of bacterial fermentation of carbohydrate in the gut [110]. SCFAs in the intestine enter the liver through the portal vein, and acetate and propionate are precursors for fatty acid synthesis and gluconeogenesis, promoting liver fat accumulation [111]. Furthermore, SCFAs bind to G protein-coupled receptors of intestinal neuroendocrine L cells to secrete peptide YY and glucagon-like peptide-1 (GLP-1), which promote nutrient absorption and liver fat generation [112]. Butyrate may activate the AMP-activated protein kinase (AMPK) pathway in the liver, leading to the inhibition of oxidative stress and inflammation, upregulation of fatty acid oxidation, downregulation of fat synthesis genes, and reduced hepatosteatosis [113]. Interestingly, patients with NAFLD and severe hepatic fibrosis had more acetate in the stool, while those with milder severity of NAFLD had more SCFAs in butyrate and propionate [114]. Moreover, the concentration of ethanol in the blood of patients with NAFLD increased, and the bacteria Proteobacteria, which could produce ethanol, also tended to increase in patients with steatohepatitis. Ethanol destroys the tight binding protein of the intestinal wall, increases the intestinal permeability, and increases the endotoxin entering blood and the liver, leading to liver inflammation [115].

Adipose tissue-liver axis

Adipose tissues secrete adiponectin, leptin, and some proinflammatory cytokines, such as IL-6 and TNFα, which would influence the liver. Adiponectin binds to adiponectin receptors 1 and 2, respectively activates AMPK and PPAR-alpha pathways in the liver, and stimulate glucose use and fatty acid oxidation [116,117]. Adiponectin also increases carnitine palmitoyltransferase I activity, enhances hepatic fatty acid oxidation, and decreases the activities of acetyl-CoA carboxylase and fatty acid synthase [118]. However, adiponectin produced mainly from white adipose tissue is decreased in NASH patients [119]. When obesity develops, leptin secreted from white fatty tissue is increased to inhibit appetite and increase fatty acid oxidation [120]. However, in obese individuals, leptin resistance develops, and the increased leptin would exert proinflammatory activity. The serum leptin levels are positively associated with the severity of liver inflammation and fibrosis [121,122]. Leptin augments the endothelin-1-induced contraction of HSCs [123]. Adipocytes also secrete TNFα [124], which can increase insulin resistance and have pro-inflammatory effects [125]. TNFα increased the gene expression of Mcp1, Tgfb1, and Timp1 in hepatocytes, and the Tnf knockout improved glucose tolerance and significantly reduced the prevalence of hepatic steatosis and fibrosis in mice, indicating that TNFα plays a role in the development and progression of NASH [126]. IL-6 can be secreted from adipocytes, which can then increase the macrophage infiltration of adipose tissue [127]. IL-6 infusion induces hepatic insulin resistance through increased adipose tissue lipolysis [128]. These data suggest that IL-6 is involved in the pathogenesis of hepatic insulin resistance.

Renin-angiotensin system (RAS)

Hypertensive patients with biopsy-proven NAFLD on baseline RAS blockers had less advanced hepatic fibrosis [129]. Recently, a large retrospective study showed that angiotensin-converting enzyme inhibitors/angiotensin receptor blockers were associated with lower risk of hepatocellular carcinoma and cirrhotic complications in patients with NAFLD [130]. These data suggested a beneficial effect of RAS blockers in NAFLD. Transgenic hypertensive rats overexpressing the mouse renin gene with elevated levels of tissue angiotensin II developed hepatic steatosis, inflammation, and fibrosis [131]. The mice lacking the renin gene fed with high-fat diet had decreased liver fat [132]. Aliskiren, a direct renin inhibitor, reduced hepatic steatosis in high-fat diet-fed mice and fibrosis in mice fed with methionine-choline-deficient diet [133,134]. When renin or prorenin binds to the (pro)renin receptor (PRR), in addition to increasing the production and role of angiotensin (ANG II dependent pathway), it activates TGFβ, plasminogen activator inhibitor-1 (PAI-1), fibronectin, and collagen I independently from Ang II (ANG II independent pathway) [135-137]. Our group found that PRR contributed to liver fibrosis and HSC activation, and its down-regulation attenuated liver fibrosis through inactivation of the ERK/TGFβ1/Smad3 pathway [138]. These results indicate that renin and prorenin can directly activate renin (pro) receptor-related intracellular signaling pathways, including ERK, TGFβ, cyclooxygenease2, fibronectin, collagen I, and PAI-1 independently of angiotensin II to induce fibrosis. Moreover, Ren et al. [139] used N-acetylgalactosamine modified antisense oligonucleotides to suppress PRR expression in hepatocytes of high-fat diet-fed C57BL/6 mice, and found that PRR inhibition reduced acetyl-CoA carboxylase and pyruvate desorption hydrogenase protein expression. This change reprogrammed liver lipid metabolism, resulting in reduced lipid synthesis and increased fatty acid oxidation. As a result, liver PRR suppression attenuated dietinduced obesity and fatty liver [139]. The proposed pathogenesis that is involved from steatosis to fibrosis in patients with NAFLD is shown in Figure 1.

PROGRESSION OF NASH TO HCC

NASH is now the most common risk factor for HCC in the United States [140]. The potential pathways linking NASH to HCC include chronic inflammation of the liver [141], alternations in immune response, lipid metabolism and gut microbiome [142], and genetic factors. Enhanced IL-6 and TNF production during NAFLD cause hepatic inflammation and activation of the oncogenic transcription factor STAT3 [143]. ER stress contributes to NASH-driven hepatic tumorigenesis via TNFR1 [144]. The hepatic oxidative DNA damage was increased in patients with NASH who developed HCC [145]. The unconventional prefoldin RPB5 interactor-induced DNA damage in hepatocytes triggered inflammation via T helper 17 lymphocytes and interleukin 17A, contributing to NASH and HCC development [146]. Furthermore, NAFLD caused a selective loss of intrahepatic CD4(+) but not CD8(+) T lymphocytes, which led to accelerated hepatocarcinogenesis [147]. Neutrophil infiltration was characterized in NASH-HCC and can exist in both tumor promoting and suppressing states [148]. Fatty acid accumulation increased junctional protein associated with coronary artery disease, leading to the activation of Yes-associated protein 1 and tumor growth [149]. Dysregulated mammalian target of rapamycin stimulated sphingolipid and glycerophospholipid synthesis, leading to steatosis and HCC [150]. In NASH-driven HCC, metabolic reprogramming mediated by the downregulation of carnitine palmitoyltransferase 2 enables HCC cells to escape lipotoxicity and promotes hepatocarcinogenesis [151]. MicroRNA-21 can promote hepatic lipid accumulation and cancer progression by interacting with the sHbp1-p53-Srebp1c pathway [152]. The intestinal dysbiosis, gut permeability changes, and lipopolysaccharides translocation to the liver in NASH may increase secretion of the epiregulin growth factor, which triggers tumor hepatocyte proliferation [153]. Moreover, carriage of the PNPLA3 rs738409 C>G polymorphism is associated with a greater risk of NASH-HCC [154].

TREATMENT FOR NASH

Non-pharmacological therapy

Lifestyle modification

Lifestyle changes by eating less and exercising more to achieve weight loss remain the cornerstone of clinical care. Hypocaloric diet with a reduction of body weight decreased total body fat, visceral fat, and intrahepatic lipid content [155]. Some existing guidelines suggest restriction of energy by 1,200–1,500 kcal/day or a reduction of 500–1,000 kcal/day to achieve weight loss [1,156-158]. Weight reduction is beneficial for both non-obese (3–10%) [159] and obese patients (≥0%) [160,161]. Other dietary compositions that may be beneficial for NAFLD includes omega-3 PUFA and coffee. Omega-3 PUFA has been shown to increase insulin sensitivity [162] and ameliorate steatohepatitis in experimental studies [163,164]. One meta-analysis involving nine studies with 355 patients showed decreased liver fat in patients with PUFA treatment [165]. Coffee is not only associated with a reduced risk of NAFLD but also decreased risk of liver fibrosis among patients with NAFLD [166,167]. Regular exercise helps to enhance the effects of diet modifications. Physical activity with a target at least 150 min/week of moderate-intensity or 75–150 min/week of vigorous-intensity aerobic exercise is suggested [1,156-158]. Both aerobic and resistance exercises reduce the hepatic fat content [168,169]. In addition, the intensity of exercise may be more important than the duration or total volume [170]. In conclusion, lifestyle interventions to promote weight loss, which include both diet and exercise, are proven therapeutic strategies to improve fatty liver disease.

Surgery

Bariatric surgery provides sustained and durable weight loss and improving obesity-related diseases [171,172]. Currently, the most commonly performed bariatric procedures are laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass. Two meta-analyses showed that bariatric surgery resulted in a biopsy-confirmed resolution of steatosis (56–66%), inflammation (45–50%), ballooning degeneration (49–76%), and fibrosis (25–40%), as well as reduction of NAFLD activity score (NAS) [173,174]. A higher rate of improvement in steatosis and hepatic fibrosis was observed in Asian countries compared to non-Asian countries [174]. In addition, bariatric surgery was associated with decreased progression of NAFLD to cirrhosis [175] and reduced risks of any cancer and obesity-related cancer in NAFLD patients with severe obesity, particularly in cirrhotic patients [176]. However, new or worsening cases of NAFLD were found in 12% of patients after bariatric surgery [173]. Bariatric surgery was associated with a significantly lower risk of incident major adverse liver outcomes (2.3% vs. 9.6% at 10 years) and major adverse cardiovascular events (8.5% vs. 15.7% at 10 years), as compared with non-surgical management [177].

Endoscopic therapy

Endoscopic bariatric therapies, including intragastric balloons (IGB), endoscopic sleeve gastroplasty (ESG), duodenal mucosal resurfacing (DMR), and duodenal-Jejunal bypass liner (DJBL), were recently introduced as less invasive modalities to treat obesity and metabolic comorbidities. In a meta-analysis, improvement in steatosis and NAS were seen in 79.2% and 83.5% of patients receiving IGB, respectively [178]. Improvement of fibrosis for 1.5 stage by MR elastography was seen in 50% of patients with NAFLD after IGB placement [179]. ESG reduced the body weight by up to 15% and improved hepatic steatosis and fibrosis at 2 years of follow-up in obese patients with NAFLD [180]. Studies for efficacy and safety of ESG (NCT03426111; NCT04653311) and the comparison of ESG vs. LSG (NCT04060368) in patients with NASH are ongoing. DMR has been shown to reduce alanine aminotransferase, aspartate aminotransferase, and fibrosis-4 scores in patients with diabetes mellitus [181]. Recently, an observational study of 32 obese patients with diabetes mellitus who underwent DJBL showed improved non-invasive markers of steatosis and NASH, but not fibrosis. The role of DJBL on NAFLD needs to be further evaluated [182].

Fecal microbiota transplantation

Some studies have suggested that fecal transplantation helps ameliorate steatohepatitis [183,184]. A randomized controlled trial (RCT) using allogenic fecal microbiota transplantation (FMT) from lean vegan donors for patients with NAFLD through duodenal infusion found that there was no significant improvement in NAS, steatosis, and fibrosis scores. However, they observed a trend of improving necro-inflammatory scores and beneficial changes in hepatic gene expression and plasma metabolites involved in inflammation and lipid metabolism following allogenic FMT [185]. Another RCT using allogenic FMT via endoscopic duodenal infusion in patients with NAFLD found that FMT did not improve insulin resistance and hepatic steatosis but reduced small intestinal permeability at 6 months of follow-up [186].

Pharmacological therapy

The pharmacological agents predominantly target the following four mechanisms: 1) hepatic fat accumulation; 2) oxidative stress, inflammation, and apoptosis; 3) gut-liver axis, including bile acids, gut microbiomes, and metabolic endotoxemia; and 4) hepatic fibrosis [187]. The agents targeting different pathways are described below, and those with promising results are summarized in Table 1.

Agents targeting hepatic fat accumulation

Pioglitazone, a PPAR γ agonist, improved hepatic steatosis, inflammation, and hepatocellular ballooning [188,189]. Similar effects were found in Asian NASH patients [190]. In the phase 3 RESOLVE-IT trial, Elafibranor, a dual PPAR α/δ agonist, failed to achieve NASH resolution [191]. Pemafibrate, a selective PPAR α modulator, did not decrease liver fat but caused a significant reduction in fibrosis for 6.2% of magnetic resonance elastography-based liver stiffness [192]. Lanifibranor, a pan-PPAR agonist, significantly decreased the steatosis-activity-fibrosis activity score for at least 2 points in 55% of the patients at 24 weeks [193].

GLP-1 agonists increase insulin secretion, inhibit glucagon secretion, delay gastric emptying, and decrease appetite. NASH resolution was observed in 39% of patients who received liraglutide for 48 weeks and in 59% of patients who received semaglutide for 72 weeks [194,195]. However, fibrosis improvement was insignificant in both studies.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors increase the urinary excretion of glucose. A meta-analysis of 10 RCTs showed that SGLT2 inhibitors can reduce aminotransferases and hepatic fat [196].

FGF19 and FGF21 are endocrines that regulate energy homeostasis. Aldafermin, a FGF19 analogue, led to reductions of liver fat content and a trend toward fibrosis improvement [197]. Pegbelfermin and efruxifermin are long-acting, recombinant analogues of human FGF21, and both have shown effects of reducing liver fat [198,199].

Two phase IIa trials investigated the effects of acetyl-coenzyme A carboxylase (ACC) inhibitor monotherapy (PF-05221304) and combination with a diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor (PF-06865571). Both PF-05221304 monotherapy and co-administration with PF-06865571 reduced liver fat content [200].

Stearoyl-coenzyme A desaturase 1 (SCD-1) is a key enzyme that catalyzes the biosynthesis of monounsaturated fatty acids. A phase IIb trial (ARREST trial) showed that aramchol (a liver-targeted SCD-1 inhibitor) 600 mg did not cause a significant reduction in liver fat content. Nevertheless, the observed change in liver histology and biochemical improvement suggests a potential role of aramchol in treating NASH and fibrosis [201].

Thyroid hormone receptor-β (THR-β) is predominantly expressed in the hepatocytes. Resmetirom, a selective THR-β agonist, significantly reduced more than 30% of hepatic fat after 12 and 36 weeks of treatment in patients with NASH in phase II trial [202].

Agents targeting oxidative stress, inflammation, and apoptosis

Vitamin E, an antioxidative agent, demonstrated benefits on hepatic decompensation and transplant-free survival in patient with NASH [203]. The PIVENS study, which compared the effects of vitamin E, pioglitazone, and placebo in NASH patients without diabetes, showed that vitamin E (800 international units/day), but not pioglitazone, significantly improved NASH [204].

Apoptosis signaling kinase 1 (ASK1) promotes apoptosis, inflammation, and fibrosis in the liver. However, selonsertib, an ASK1 inhibitor, failed to improve fibrosis in NASH patients with bridging fibrosis or compensated cirrhosis [205].

Berberine ursodeoxycholate is an ionic salt of berberine and ursodeoxycholic acid. It reduced 4.8% of liver fat and improved glycemic control as well as liver enzymes in patients with NASH and diabetes [206].

Agents targeting gut-liver axis

In a phase IIb study, obeticholic acid (OCA), a FXR agonist, improved liver histology in 21% of NASH patients [207]. In patients with NASH and diabetes, OCA demonstrated the effects of increasing insulin sensitivity and reducing markers of liver inflammation as well as fibrosis [208]. In the interim analysis of a phase III trial, both 10-mg and 25-mg doses of OCA improved fibrosis (18% and 23%, respectively), but the NASH resolution endpoint was not met [209]. This study is ongoing to assess the clinical outcomes.

Agents targeting liver fibrosis

Caspase is a protease that is associated with apoptosis and inflammation in the liver. However, emricasan, a pan-caspase inhibitor, did not improve fibrosis or resolution of NASH [210]. Besides, for patients with NASH-related cirrhosis and severe portal hypertension, emricasan did not improve hepatic venous pressure gradient (HVPG) or liver-related outcomes [211].

In a phase IIb CENTAUR trial, a 2-year study, cenicriviroc, a dual C-C chemokine receptor types 2 and 5 antagonist, achieved ≥1-stage of fibrosis improvement without worsening of NASH after 1 year of treatment compared to placebo (20% vs. 10%) [212]. And a great proportion (60%) of the patients who achieved fibrosis response at the first year maintained fibrosis reduction at the second year [213]. The long-term impact of cenicriviroc on fibrosis needs to be further investigated.

Belapectin, a galectin-3 inhibitor, did not significantly reduce HVPG or fibrosis in patients with NASH, cirrhosis, and portal hypertension; however, in a subgroup of patients without esophageal varices, belapectin reduced HVPG as well as the development of esophageal varices [214].

Information about the ongoing phase III clinical trials of promising drugs on phase II studies are listed in Table 2.

Combination therapy

NAFLD is a multifactorial disease, and combining therapies with different targets may have synergistic effects [215]. Cilofexor (FXR agonist) plus firsocostat (ACC inhibitor) led to improvements in NASH activity compared to placebo, or single agent in patients with bridging fibrosis and cirrhosis [216]. Semaglutide with firsocostat and/or cilofexor showed greater improvements in liver steatosis and liver biochemistry compared to semaglutide alone [217]. Combining ACC inhibitors and DGAT2 inhibitors reduced liver fat content and mitigated the side effect of elevated serum TGs [200].

PERSPECTIVES

As understanding of mechanisms of NASH and its fibrosis increases, more therapies will be introduced and tested in clinical trials. The pathogenesis of NASH and fibrosis is complex; therefore, it would be difficult to treat the disease using just one therapy. Combination therapy is the focus in the future development of treatment. Furthermore, better care of extra-hepatic complications of NASH, novel biomarkers for diagnosis, risk stratification and treatment responses, and more clinical trials in Asian groups should also be well researched and developed.

ACKNOWLEDGMENTS

This study was supported in part by the grants from the Ministry of Science and Technology (110-2628-B-075-016; 111-2314-B-075-051-MY3) Taiwan.

FOOTNOTES

Authors’ contribution

KC Lee and PS Wu drafted the manuscript and HC Lin revised the manuscript. All the authors read and approved the final version.

Conflicts of Interest

The authors have no conflicts to disclose.

Figure 1.

Progression of hepatic steatosis to inflammation and fibrosis in liver. Both metabolic and genetic factors contribute to the formation of hepatic steatosis. Fat accumulation in hepatocytes leads to organelles dysfunction and lipotoxicity. Then, oxidative stress species or signaling molecules are transmitted through extracellular vesicles or diffusion, activating other parenchymal and non-parenchymal cells, which subsequently causes inflammatory cascades, steatohepatitis, and liver fibrosis. On the other hand, gut-derived bacterial end-products, metabolites, gut hormones, adipose tissue-derived cytokines or adipokines, and renin-angiotensin-system all contribute to the progression from steatosis to inflammation and fibrosis. SFA, saturated fatty acid; TG, triglyceride; ER, endoplastic reticulum; HH-OPN, Hedgehog-osteopontin; KC, Kupffer cell; HSC, hepatic stellate cell.

Table 1.

Promising pharmacological therapies for NAFLD or NASH

Table 1.
Type of drug	Mechanism of action	Drug name	Study design	Study outcome	Reference
PPAR agonist	PPAR-γ: ↑ insulin sensitivity modulates adipose tissue distribution	Pioglitazone (PPAR-γ agonist)	RCT; NASH, prediabetes/DM	↓ ALT/AST	[188]
			Pioglitazone vs. placebo	↓ Steatosis, ballooning necrosis, and inflammation	[189]
	PPAR-α: ↑ fatty acid β-oxidation			Fibrosis not improved
	PPAR-δ: anti-inflammatory		RCT; NASH	↓ ALT/GGT
			Pioglitazone vs. placebo	Histology improvement, including liver injury and fibrosis
		Pemafibrate (SPPARMα)	Phase II RCT; NAFLD and ↑ ALT	↓ ALT	[192]
			Phase II RCT; NAFLD and ↑ ALT	↓ Liver stiffness
			Pemafibrate vs. placebo	No significant change of liver fat
		Lanifibranor (Pan-PPAR agonist)	Phase IIb RCT; NASH (SAF-A ≥3)	↓ SAF-A score ≥2 points in lanifibranor 1,200 mg group	[193]
		Lanifibranor (Pan-PPAR agonist)	Lanifibranor vs. placebo	↓ SAF-A score ≥2 points in lanifibranor 1,200 mg group
GLP-1 agonist	↑ Insulin secretion	Liraglutide	Phase II RCT; NASH, obesity	↑ Resolution of NASH without worsening of fibrosis	[194]
	↓ Glucagon secretion	Liraglutide	Liraglutide vs. placebo	No difference in fibrosis improvement
	↓ Gastric emptying	Semaglutide	RCT, phase II; NASH (F1–F3 fibrosis)	↑ Resolution of NASH without worsening of fibrosis in semaglutide 0.4 mg group	[195]
	↓ Appetite	Semaglutide	Semaglutide vs. placebo	No difference in fibrosis improvement
SGLT2 inhibitor	↑ Urinary excretion of glucose	SGLT2 inhibitors	Meta-analysis of 10 RCTs; NAFLD, DM	↓ ALT/AST	[196]
SGLT2 inhibitor	↑ Urinary excretion of glucose	SGLT2 inhibitors	SGLT2 inhibitor vs. other antidiabetic drugs	↓ Liver fat content, visceral fat, and subcutaneous fat areas
FGF-19 analogue	↓ Bile acids synthesis	Aldafermin	Phase II RCT; NASH (NAS ≥4, F2–F3 fibrosis, and liver fat content ≥8%)	↓ ALT/AST	[197]
	↓ Hepatic gluconeogenesis			↓ Liver fat fraction on MRI-PDFF
	↓ DNL		Aldafermin vs. placebo
	↑ Fatty acid oxidation		Aldafermin vs. placebo
FGF-21 analogue	↓ Hepatic gluconeogenesis	Pegbelfermin	Phase IIa RCT; NASH (F1–F3 fibrosis, and liver fat content ≥10%), obesity	↓ Liver fat fraction on MRI-PDFF	[198]
	↑ Insulin sensitivity
	↑ Energy expenditure		Pegbelfermin vs. placebo
	↑ Mitochondria beta-oxidation in hepatocytes	Efruxifermin	Phase IIa RCT; NASH	↓ Liver fat fraction on MRI-PDFF	[199]
	↑ Mitochondria beta-oxidation in hepatocytes	Efruxifermin	Efruxifermin vs. placebo	↓ Liver fat fraction on MRI-PDFF
Acetyl-CoA carboxylase inhibitor	↓ DNL	PF-05221304	2 phase IIa RCTs; NAFLD/NASH	PF-05221304 monotherapy:	[200]
Acetyl-CoA carboxylase inhibitor	↑ Fatty acid oxidation	PF-05221304	PF-05221304 monotherapy vs. placebo	↓Liver fat on MRI-PDFF, but ↑ TG
Diacylglycerol acyltransferase 2 inhibitor	↓ Synthesis of fatty acids into TGs	PF-06865571	PF-05221304 and PF-06865571 co-administration vs. placebo	Co-administration therapy: ↓ liver fat and mitigated ACC inhibitormediated effect on TG
Stearoyl-CoA desaturase 1 inhibitor	↓ DNL	Aramchol	Phase IIb RCT; NASH	↓ Liver fat content in aramchol 600 mg group, but not significant	[201]
Stearoyl-CoA desaturase 1 inhibitor	↓ DNL	Aramchol	Aramchol vs. placebo
Selective thyroid hormone receptor-β agonist	↓ LDL, cholesterol, and TG	Resmetirom	Phase II RCT; NASH (F1–F3 fibrosis, and liver fat content ≥10%)	↓ Liver fat on MRI-PDFF	[202]
Selective thyroid hormone receptor-β agonist	↑ Fatty acid oxidation	Resmetirom	Resmetirom vs. placebo	↓ Liver fat on MRI-PDFF
Anti-oxidant	Anti-oxidative stress	Vitamin E	RCT; NASH, no DM	↓ ALT/AST for both vitamin E and pioglitazone groups	[204]
			Vitamin E vs. pioglitazone vs. placebo	NASH improvement in vitamin E group, but not in pioglitazone group
			Vitamin E vs. pioglitazone vs. placebo	Fibrosis not improved in vitamin E and pioglitazone groups
Bile acid analogue	Anti-inflammation	Berberine ursodeoxycholate	Phase II RCT; NAFLD, DM	↓ Liver fat content on MRI-PDFF	[206]
	Anti-inflammation	Berberine ursodeoxycholate	Berberine ursodeoxycholate vs. placebo	↓ Liver fat content on MRI-PDFF
	↓ DNL	Obeticholic acid (FXR agonist)	Phase III RCT; NASH (NAS ≥4, F2–F3 fibrosis or F1 with ≥1 accompanying comorbidity)	↓ Fibrosis	[209]
	↑ Fatty acid β-oxidation			No significant resolution of NASH
	↑ Cholesterol excretion		Obeticholic acid vs. placebo	No significant resolution of NASH

NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PPAR, proliferator-activated receptor; SPPARMα, selective peroxisome proliferator-activated receptor α modulator; RCT, randomized controlled trial; ALT, alanine aminotransferase; SAF-A, steatosis-activity-fibrosis activity; GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose cotransporter 2; DM, diabetes mellitus; AST, aspartate aminotransferase; FGF, fibroblast growth factor; DNL, de novo lipogenesis; NAS, NAFLD activity score; MRI, magnetic resonance imaging; PDFF, proton density fat fraction; TG, triglyceride; ACC, acetyl-coenzyme A carboxylase; LDL, low density lipoprotein; FXR, farnesoid X receptor.

Table 2.

Ongoing phase III clinical trials of pharmacological agents in patients with NAFLD or NASH

Table 2.
Agent	Mechanism	Patient	Outcome	Status	ClinicalTrials.gov identifier
Lanifibranor	Pan-PPAR agonist	NASH with stage 2–3 fibrosis without cirrhosis	NASH resolution; fibrosis improvement; liver-related events	Recruiting	NCT04849728
Semaglutide	GLP-1 agonist	NASH with stage 2–3 fibrosis	NASH resolution; fibrosis improvement; liver-related events	Recruiting	NCT04822181
Dapagliflozin	SGLT2 inhibitor	NASH and type 2 DM without cirrhosis	Histology improvement	Recruiting	NCT03723252
Resmetirom	Selective thyroid hormone receptor-β agonist	NASH without cirrhosis	NASH resolution; liver-related events	Recruiting	NCT03900429
Aramchol	Stearoyl-CoA desaturase 1 inhibitor	NASH with stage 2–3 fibrosis without cirrhosis; type 2 DM or prediabetes	NASH resolution; fibrosis improvement	Recruiting	NCT04104321
Belapectin	Galectin-3 inhibitor	NASH cirrhosis without esophageal or gastric varices	Newly developed esophageal varices	Recruiting	NCT04365868
Oltipraz	Liver X receptor alpha-inhibitor	NAFLD without cirrhosis	Liver fat	Recruiting	NCT04142749

NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PPAR, proliferator-activated receptor; GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose cotransporter 2; DM, diabetes mellitus.

Abbreviations

ACC

acetyl-coenzyme A carboxylase

AMPK

AMP-activated protein kinase

ANG

angiotensin

ASK1

apoptosis signaling kinase 1

CHOP

C/EBP homologous protein

DGAT2

diacylglycerol O-acyltransferase 2

DJBL

duodenal-Jejunal bypass liner

DMR

duodenal mucosal resurfacing

DNL

de novo lipogenesis

endoplasmic reticulum

ESG

endoscopic sleeve gastroplasty

FFA

free fatty acid

FGF

fibroblast growth factor

FMT

fecal microbiota transplantation

FXR

farnesoid X receptor

GCKR

glucokinase regulatory protein

GLP-1

glucagon-like peptide-1

HCC

hepatocellular carcinoma

hedgehog

HSC

hepatic stellate cell

HSD17B13

hydroxysteroid 17- beta dehydrogenase 13

HVPG

hepatic venous pressure gradient

IGB

intragastric balloons

interleukin

IRE1

inositol-requiring enzyme 1

IRGM

immunity-related GTPase M

Kupffer cell

LSG

laparoscopic sleeve gastrectomy

MBOAT7

membrane-bound O-acyltransferase domain-containing protein 7

miRNA

microRNA

NAFLD

non-alcoholic fatty liver disease

NAS

NAFLD activity score

NASH

non-alcoholic steatohepatitis

NEFA

non-esterified fatty acid

OCA

obeticholic acid

PAI-1

plasminogen activator inhibitor-1

PERK

protein kinase R (double-stranded RNA-activated protein kinase)-like ER kinases

PNPLA3

patatin-like phospholipase domaincontaining 3

PPAR

proliferator-activated receptor

PRR

(pro)renin receptor

PUFA

polyunsaturated fatty acid

RAS

renin-angiotensin system

RCT

randomized controlled trial

SCD-1

stearoyl-coenzyme A desaturase 1

SCFA

short-chain fatty acid

SFA

saturated fatty acid

SGLT2

sodium-glucose cotransporter 2

SNP

single nucleotide polymorphism

SREBP1c

sterol receptor binding protein 1-c

triglyceride

TGF

transforming growth factor

THR-β

thyroid hormone receptor-β

TLR

toll-like receptor

TM6SF2

transmembrane 6 superfamily 2

TNF

tumor necrosis factor

TNFR1

TNF receptor 1

UPR

unfolded protein response

VLDL

very-low-density lipoprotein

XBP-1

X-box-binding protein 1

ω6

omega-6

REFERENCES

1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-357.
Article
PubMed
PDF
2. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
Article
PubMed
PMC
3. Lemoinne S, Friedman SL. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Curr Opin Pharmacol 2019;49:60-70.
Article
PubMed
4. Westerbacka J, Lammi K, Häkkinen AM, Rissanen A, Salminen I, Aro A, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005;90:2804-2809.
Article
PubMed
5. van der Meer RW, Hammer S, Lamb HJ, Frölich M, Diamant M, Rijzewijk LJ, et al. Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men. J Clin Endocrinol Metab 2008;93:2702-2708.
Article
PubMed
PDF
6. Lindeboom L, Nabuurs CI, Hesselink MK, Wildberger JE, Schrauwen P, Schrauwen-Hinderling VB. Proton magnetic resonance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein. Am J Clin Nutr 2015;101:65-71.
Article
PubMed
7. Hernández EA, Kahl S, Seelig A, Begovatz P, Irmler M, Kupriyanova Y, et al. Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance. J Clin Invest 2017;127:695-708.
Article
PubMed
PMC
8. Kaikkonen JE, Würtz P, Suomela E, Lehtovirta M, Kangas AJ, Jula A, et al. Metabolic profiling of fatty liver in young and middle-aged adults: cross-sectional and prospective analyses of the young finns study. Hepatology 2017;65:491-500.
Article
PubMed
PDF
9. Rosqvist F, Kullberg J, Ståhlman M, Cedernaes J, Heurling K, Johansson HE, et al. Overeating saturated fat promotes fatty liver and ceramides compared with polyunsaturated fat: a randomized trial. J Clini Endocrinol Metab 2019;104:6207-6219.
Article
PDF
10. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46:1081-1090.
Article
PubMed
11. Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a populationbased study. Aliment Pharmacol Ther 2012;36:772-781.
Article
PubMed
12. Ryu S, Chang Y, Jung HS, Yun KE, Kwon MJ, Choi Y, et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatology 2015;63:1229-1237.
Article
13. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
PubMed
14. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-642.
Article
PubMed
PDF
15. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351.
Article
PubMed
PMC
16. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91:4753-4761.
PubMed
17. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 1997;99:846-854.
Article
PubMed
PMC
18. Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 2005;115:1139-1142.
Article
PubMed
PMC
19. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004;432:1027-1032.
Article
PubMed
PDF
20. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
Article
PubMed
PMC
PDF
21. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.
Article
PubMed
PMC
22. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 2011;43:1131-1138.
PubMed
PMC
23. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, OrhoMelander M, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009;18:4081-4088.
Article
PubMed
PMC
24. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46:352-356.
Article
PubMed
PMC
PDF
25. Mahdessian H, Taxiarchis A, Popov S, Silveira A, FrancoCereceda A, Hamsten A, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A 2014;111:8913-8918.
Article
PubMed
PMC
26. Lin YC, Chang PF, Lin HF, Liu K, Chang MH, Ni YH. Variants in the autophagy-related gene IRGM confer susceptibility to non-alcoholic fatty liver disease by modulating lipophagy. J Hepatol 2016;65:1209-1216.
Article
PubMed
27. Bellini G, Miraglia Del Giudice E, Nobili V, Rossi F. The IRGM rs10065172 variant increases the risk for steatosis but not for liver damage progression in Italian obese children. J Hepatol 2017;67:653-655.
Article
PubMed
28. Luukkonen PK, Qadri S, Ahlholm N, Porthan K, Mannisto V, Sammalkorpi H, et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of nonalcoholic fatty liver disease. J Hepatol 2022;76:526-535.
Article
PubMed
PMC
29. Ma J, Nano J, Ding J, Zheng Y, Hennein R, Liu C, et al. A peripheral blood DNA methylation signature of hepatic fat reveals a potential causal pathway for nonalcoholic fatty liver disease. Diabetes 2019;68:1073-1083.
Article
PubMed
PMC
PDF
30. Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015;64:800-812.
Article
PubMed
31. Castano C, Kalko S, Novials A, Parrizas M. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci U S A 2018;115:12158-12163.
Article
PubMed
PMC
32. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98.
Article
PubMed
33. Latorre J, Moreno-Navarrete JM, Mercader JM, Sabater M, Rovira O, Girones J, et al. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD. Int J Obes (Lond) 2017;41:620-630.
Article
PubMed
PDF
34. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012;122:2871-2883.
Article
PubMed
PMC
35. Kim YS, Nam HJ, Han CY, Joo MS, Jang K, Jun DW, et al. Liver X receptor alpha activation inhibits autophagy and lipophagy in hepatocytes by dysregulating autophagy-related 4B cysteine peptidase and Rab-8B, reducing mitochondrial fuel oxidation. Hepatology 2021;73:1307-1326.
Article
PubMed
PDF
36. Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature 2016;529:326-335.
Article
PubMed
PDF
37. Lebeaupin C, Vallee D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol 2018;69:927-947.
Article
PubMed
38. Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008;134:568-576.
Article
PubMed
39. Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, et al. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol 2010;52:586-593.
Article
PubMed
PMC
40. Volmer R, van der Ploeg K, Ron D. Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. Proc Natl Acad Sci U S A 2013;110:4628-4633.
Article
PubMed
PMC
41. Latif MU, Schmidt GE, Mercan S, Rahman R, Gibhardt CS, Stejerean-Todoran I, et al. NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. Gut 2022;71:2561-2573.
Article
PubMed
PMC
42. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011;14:804-810.
Article
PubMed
PMC
43. Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015;21:739-746.
Article
PubMed
44. Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999-1007.
Article
PubMed
45. Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, et al. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest 2015;125:4447-4462.
Article
PubMed
PMC
46. Martel C, Allouche M, Esposti DD, Fanelli E, Boursier C, Henry C, et al. Glycogen synthase kinase 3-mediated voltage-dependent anion channel phosphorylation controls outer mitochondrial membrane permeability during lipid accumulation. Hepatology 2013;57:93-102.
Article
PubMed
47. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008;47:1495-1503.
Article
PubMed
PMC
48. Meex RCR, Blaak EE. Mitochondrial dysfunction is a key pathway that links saturated fat intake to the development and progression of NAFLD. Mol Nutr Food Res 2021;65:e1900942.
Article
PubMed
PDF
49. Peng KY, Watt MJ, Rensen S, Greve JW, Huynh K, Jayawardana KS, et al. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression. J Lipid Res 2018;59:1977-1986.
Article
PubMed
PMC
50. Chocian G, Chabowski A, Zendzian-Piotrowska M, Harasim E, Lukaszuk B, Gorski J. High fat diet induces ceramide and sphingomyelin formation in rat’s liver nuclei. Mol Cell Biochem 2010;340:125-131.
Article
PubMed
PDF
51. Chavez JA, Summers SA. A ceramide-centric view of insulin resistance. Cell Metab 2012;15:585-594.
Article
PubMed
52. Arora AS, Jones BJ, Patel TC, Bronk SF, Gores GJ. Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology 1997;25:958-963.
Article
PubMed
53. Tovoli F, Napoli L, Negrini G, D’Addato S, Tozzi G, D’Amico J, et al. A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease. Int J mol Sci 2017;18:1134.
Article
PubMed
PMC
54. Baratta F, Pastori D, Del Ben M, Polimeni L, Labbadia G, Di Santo S, et al. Reduced lysosomal acid lipase activity in adult patients with non-alcoholic fatty liver disease. EBioMedicine 2015;2:750-754.
Article
PubMed
PMC
55. Wang X, Zhang X, Chu ESH, Chen X, Kang W, Wu F, et al. Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. FASEB J 2018;32:37-51.
Article
PubMed
PDF
56. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185-194.
PubMed
57. Hirsova P, Ibrabim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res 2016;57:1758-1770.
Article
PubMed
PMC
58. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature 2009;458:1131-1135.
Article
PubMed
PMC
PDF
59. Li S, Dou X, Ning H, Song Q, Wei W, Zhang X, et al. Sirtuin 3 acts as a negative regulator of autophagy dictating hepatocyte susceptibility to lipotoxicity. Hepatology 2017;66:936-952.
Article
PubMed
PDF
60. Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. How does hepatic lipid accumulation lead to lipotoxicity in nonalcoholic fatty liver disease? Hepatol Int 2021;15:21-35.
Article
PubMed
PDF
61. Cao L, Quan XB, Zeng WJ, Yang XO, Wang MJ. Mechanism of hepatocyte apoptosis. J Cell Death 2016;9:19-29.
Article
PubMed
PMC
PDF
62. Rada P, Gonzalez-Rodriguez A, Garcia-Monzon C, Valverde AM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis 2020;11:802.
Article
PubMed
PMC
PDF
63. Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021;385:1559-1569.
Article
PubMed
PMC
64. Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019;17:543-550 e2.
Article
PubMed
65. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-654 e1-e9.
Article
PubMed
66. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-379.
Article
PubMed
67. Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun 2020;4:478-492.
Article
PubMed
PMC
PDF
68. Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 2018;68:280-295.
Article
PubMed
69. Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Werneburg NW, et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology 2016;150:956-967.
Article
PubMed
70. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-663.
Article
PubMed
71. Kwon H, Song K, Han C, Chen W, Wang Y, Dash S, et al. Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease. Hepatology 2016;63:1155-1169.
Article
PubMed
PDF
72. Syn WK, Jung Y, Omenetti A, Abdelmalek M, Guy CD, Yang L, et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009;137:1478-1488 e8.
Article
PubMed
73. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011;53:106-115.
Article
PubMed
74. Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012;61:1323-1329.
Article
PubMed
PMC
75. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-3025.
Article
PubMed
PMC
76. Hetherington AM, Sawyez CG, Zilberman E, Stoianov AM, Robson DL, Borradaile NM. Differential lipotoxic effects of palmitate and oleate in activated human hepatic stellate cells and epithelial hepatoma cells. Cell Physiol Biochem 2016;39:1648-1662.
Article
PubMed
PDF
77. Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, Narimatsu K, et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014;59:154-169.
Article
PubMed
78. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-744.
Article
PubMed
79. Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999;29:1743-1751.
Article
PubMed
80. Cai CX, Buddha H, Castelino-Prabhu S, Zhang Z, Britton RS, Bacon BR, et al. Activation of insulin-PI3K/akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis. Dig Dis Sci 2017;62:968-978.
Article
PubMed
PDF
81. Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 2014;23:4077-4085.
Article
PubMed
PMC
82. Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 2016;150:1219-1230 e6.
Article
PubMed
PMC
83. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 2012;142:938-946.
Article
PubMed
PMC
84. Thangapandi VR, Knittelfelder O, Brosch M, Patsenker E, Vvedenskaya O, Buch S, et al. Loss of hepatic Mboat7 leads to liver fibrosis. Gut 2021;70:940-950.
Article
PubMed
85. Fondevila MF, Fernandez U, Gonzalez-Rellan MJ, Da Silva Lima N, Buque X, Gonzalez-Rodriguez A, et al. The L-αlysophosphatidylinositol/G protein-coupled receptor 55 system induces the development of nonalcoholic steatosis and steatohepatitis. Hepatology 2021;73:606-624.
Article
PubMed
PDF
86. Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5:4309.
Article
PubMed
PDF
87. Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 2018;378:1096-1106.
PubMed
PMC
88. Pirola CJ, Garaycoechea M, Flichman D, Arrese M, San Martino J, Gazzi C, et al. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease. J Lipid Res 2019;60:176-185.
Article
PubMed
89. Luukkonen PK, Tukiainen T, Juuti A, Sammalkorpi H, Haridas PAN, Niemela O, et al. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight 2020;5:e132158.
Article
PubMed
PMC
90. Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S, et al. 17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease. Hepatology 2019;69:1504-1519.
Article
PubMed
PDF
91. Zeybel M, Hardy T, Robinson SM, Fox C, Anstee QM, Ness T, et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics 2015;7:25.
Article
PubMed
PMC
PDF
92. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013;11:868-875 e1-e3.
Article
PubMed
93. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013;58:120-127.
Article
PubMed
94. Mao JW, Tang HY, Zhao T, Tan XY, Bi J, Wang BY, et al. Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease. Int J Clin Exp Pathol 2015;8:3648-3658.
PubMed
PMC
95. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009;58:704-720.
Article
PubMed
96. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-185.
Article
PubMed
PMC
PDF
97. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008;28:1026-1033.
Article
PubMed
PMC
98. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997;94:2557-2562.
Article
PubMed
PMC
99. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007;47:571-579.
Article
PubMed
PMC
100. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010;139:323-334 e327.
Article
PubMed
101. Hsieh YC, Lee KC, Wu PS, Huo TI, Huang YH, Hou MC, et al. Eritoran attenuates hepatic inflammation and fibrosis in mice with chronic liver injury. Cells 2021;10:1562.
Article
PubMed
PMC
102. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:1324-1332.
Article
PubMed
PDF
103. Mehta G, Gustot T, Mookerjee RP, Garcia-Pagan JC, Fallon MB, Shah VH, et al. Inflammation and portal hypertension - the undiscovered country. J Hepatology 2014;61:155-163.
Article
104. Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol 2019;71:1216-1228.
Article
PubMed
PMC
105. Yuan J, Baker SS, Liu W, Alkhouri R, Baker RD, Xie J, et al. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2014;29:1292-1298.
Article
PubMed
PDF
106. Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol 2015;1:222-232.
Article
PubMed
PMC
107. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006;103:12511-12516.
Article
PubMed
PMC
108. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006;103:1006-1011.
Article
PubMed
PMC
109. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17:1581-1591.
Article
PubMed
PMC
110. Yajima M, Karaki SI, Tsuruta T, Kimura S, Nio-Kobayashi J, Kuwahara A, et al. Diversity of the intestinal microbiota differently affects non-neuronal and atropine-sensitive ileal contractile responses to short-chain fatty acids in mice. Biomed Res 2016;37:319-328.
Article
PubMed
111. den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A, van Eunen K, et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol 2013;305:G900-G910.
Article
PubMed
112. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A 2008;105:16767-16772.
Article
PubMed
PMC
113. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009;58:1509-1517.
Article
PubMed
PMC
PDF
114. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for noninvasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017;25:1054-1062 e5.
Article
PubMed
PMC
115. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-609.
Article
PubMed
116. Passos MC, Goncalves MC. Regulation of insulin sensitivity by adiponectin and its receptors in response to physical exercise. Horm Metab Res 2014;46:603-608.
Article
PubMed
117. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
Article
PubMed
PDF
118. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
Article
PubMed
PMC
119. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
PubMed
120. Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013;417:80-84.
Article
PubMed
121. Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014;63:207-217.
Article
PubMed
122. Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 2016;59:30-43.
Article
PubMed
PDF
123. Yang YY, Tsai TH, Huang YT, Lee TY, Chan CC, Lee KC, et al. Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats. Hepatology 2012;55:1540-1550.
Article
PubMed
124. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801.
Article
PubMed
PMC
125. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010;28:179-185.
Article
PubMed
PDF
126. Kakino S, Ohki T, Nakayama H, Yuan X, Otabe S, Hashinaga T, et al. Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model. Horm Metab Res 2018;50:80-87.
Article
PubMed
127. Han MS, White A, Perry RJ, Camporez JP, Hidalgo J, Shulman GI, et al. Regulation of adipose tissue inflammation by interleukin 6. Proc Natl Acad Sci U S A 2020;117:2751-2760.
Article
PubMed
PMC
128. Perry RJ, Camporez JG, Kursawe R, Titchenell PM, Zhang D, Perry CJ, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 2015;160:745-758.
Article
PubMed
PMC
129. Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, et al. Renin-angiotensin system and fibrosis in nonalcoholic fatty liver disease. Liver Int 2015;35:979-985.
Article
PubMed
PDF
130. Zhang X, Wong GL, Yip TC, Tse YK, Liang LY, Hui VW, et al. Angiotensin-converting enzyme inhibitors prevent liverrelated events in nonalcoholic fatty liver disease. Hepatology 2021;76:469-482.
Article
PDF
131. Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, et al. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008;49:417-428.
Article
PubMed
PMC
132. Takahashi N, Li F, Hua K, Deng J, Wang CH, Bowers RR, et al. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 2007;6:506-512.
Article
PubMed
PMC
133. Lee KC, Chan CC, Yang YY, Hsieh YC, Huang YH, Lin HC. Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet. PLoS One 2013;8:e77817.
Article
PubMed
PMC
134. Lee KC, Hsieh YC, Yang YY, Chan CC, Huang YH, Lin HC. Aliskiren reduces hepatic steatosis and epididymal fat mass and increases skeletal muscle insulin sensitivity in high-fat diet-fed mice. Sci Rep 2016;6:18899.
Article
PubMed
PMC
PDF
135. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-1427.
Article
PubMed
PMC
136. Oliver JA. Receptor-mediated actions of renin and prorenin. Kidney Int 2006;69:13-15.
Article
PubMed
137. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptormediated, angiotensin II-independent mechanisms. Kidney Int 2006;69:105-113.
PubMed
138. Hsieh YC, Lee KC, Lei HJ, Lan KH, Huo TI, Lin YT, et al. (Pro)renin receptor knockdown attenuates liver fibrosis through inactivation of ERK/TGF-β1/SMAD3 pathway. Cell Mol Gastroenterol Hepatol 2021;12:813-838.
Article
PubMed
PMC
139. Ren L, Sun Y, Lu H, Ye D, Han L, Wang N, et al. (Pro)renin receptor inhibition reprograms hepatic lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis. Circ Res 2018;122:730-741.
Article
PubMed
PMC
140. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123-133.
Article
PubMed
PDF
141. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019;16:411-428.
Article
PubMed
PDF
142. Schwabe RF, Greten TF. Gut microbiome in HCC - mechanisms, diagnosis and therapy. J Hepatol 2020;72:230-238.
Article
PubMed
143. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208.
Article
PubMed
PMC
144. Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 2014;26:331-343.
Article
PubMed
PMC
145. Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol 2013;48:1249-1258.
Article
PubMed
PDF
146. Gomes AL, Teijeiro A, Burén S, Tummala KS, Yilmaz M, Waisman A, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 2016;30:161-175.
Article
PubMed
147. Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 2016;531:253-257.
Article
PubMed
PMC
PDF
148. Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, et al. CXCR2 inhibition enables NASH-HCC Immunotherapy. Gut 2022;71:2093-2106.
Article
PubMed
149. Ye J, Li TS, Xu G, Zhao YM, Zhang NP, Fan J, et al. JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity. Cancer Res 2017;77:5287-5300.
Article
PubMed
PDF
150. Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, et al. mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell 2017;32:807-823 e12.
Article
PubMed
151. Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut 2018;67:1493-1504.
Article
PubMed
152. Wu H, Ng R, Chen X, Steer CJ, Song G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut 2016;65:1850-1860.
Article
PubMed
153. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504-516.
Article
PubMed
PMC
154. Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75-81.
Article
PubMed
155. Haufe S, Engeli S, Kast P, Böhnke J, Utz W, Haas V, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011;53:1504-1514.
Article
PubMed
156. European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-1402.
Article
PubMed
157. Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14:889-919.
Article
PubMed
PDF
158. Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology 2021;160:912-918.
Article
PubMed
159. Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol 2018;69:1349-1356.
Article
PubMed
160. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2013;59:536-542.
Article
PubMed
161. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, TorresGonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367-378 e5.
Article
PubMed
162. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 1987;237:885-888.
Article
PubMed
163. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003;38:1529-1539.
Article
PubMed
164. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004;39:608-616.
Article
PubMed
165. Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;56:944-951.
Article
PubMed
166. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012;55:429-436.
Article
PubMed
167. Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:e8-e12.
Article
PubMed
168. Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 2017;66:142-152.
Article
PubMed
169. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012;55:1738-1745.
Article
PubMed
170. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011;106:460-468.
Article
PubMed
PMC
171. Puzziferri N, Roshek TB 3rd, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014;312:934-942.
Article
PubMed
PMC
172. O’Brien PE, Hindle A, Brennan L, Skinner S, Burton P, Smith A, et al. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20- year outcomes after adjustable gastric banding. Obes Surg 2019;29:3-14.
Article
PubMed
PDF
173. Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019;17:1040-1060 e11.
Article
PubMed
174. Zhou H, Luo P, Li P, Wang G, Yi X, Fu Z, et al. Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis. Obes Surg 2022;32:1872-1883.
Article
PubMed
PDF
175. Wirth KM, Sheka AC, Kizy S, Irey R, Benner A, Sieger G, et al. Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: a retrospective cohort analysis. Ann Surg 2020;272:32-39.
PubMed
176. Rustgi VK, Li Y, Gupta K, Minacapelli CD, Bhurwal A, Catalano C, et al. Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity. Gastroenterology 2021;161:171-184 e10.
Article
PubMed
177. Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 2021;326:2031-2042.
Article
PubMed
PMC
178. Chandan S, Mohan BP, Khan SR, Facciorusso A, Ramai D, Kassab LL, et al. Efficacy and safety of intragastric balloon (IGB) in non-alcoholic fatty liver disease (NAFLD): a comprehensive review and meta-analysis. Obes Surg 2021;31:1271-1279.
Article
PubMed
PDF
179. Bazerbachi F, Vargas EJ, Rizk M, Maselli DB, Mounajjed T, Venkatesh SK, et al. Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2021;19:146-154 e4.
Article
PubMed
180. Hajifathalian K, Mehta A, Ang B, Skaf D, Shah SL, Saumoy M, et al. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointest Endosc 2021;93:1110-1118.
Article
PubMed
181. van Baar ACG, Beuers U, Wong K, Haidry R, Costamagna G, Hafedi A, et al. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. JHEP Rep 2019;1:429-437.
Article
PubMed
PMC
182. Karlas T, Petroff D, Feisthammel J, Beer S, Blüher M, Schütz T, et al. Endoscopic bariatric treatment with duodenal-jejunal bypass liner improves non-invasive markers of non-alcoholic Steatohepatitis. Obes Surg 2022;32:2495-2503.
Article
PubMed
PMC
PDF
183. Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, et al. Total fecal microbiota transplantation alleviates high-fat dietinduced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep 2017;7:1529.
Article
PubMed
PMC
PDF
184. Mocanu V, Zhang Z, Deehan EC, Kao DH, Hotte N, Karmali S, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med 2021;27:1272-1279.
Article
PubMed
PDF
185. Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis. Hepatol Commun 2020;4:1578-1590.
Article
PubMed
PMC
PDF
186. Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol 2020;115:1055-1065.
Article
PubMed
187. Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018;53:362-376.
Article
PubMed
PDF
188. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.
Article
PubMed
189. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-1184.
Article
PubMed
190. Huang JF, Dai CY, Huang CF, Tsai PC, Yeh ML, Hsu PY, et al. Firstin-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. Hepatol Int 2021;15:1136-1147.
Article
PubMed
PDF
191. Harrison SA, Ratziu V, Bedossa P, Dufour JF, Kruger F, Schattenberg JM, et al. RESOLVE-IT phase 3 trial of elafibranor in NASH: final results of the week 72 interim surrogate efficacy analysis; 2020 Nov 13 - Nov 16. Virginia: AASLD The Liver Meeting; 2020 Nov. 23 p.
192. Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, et al. Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2021;54:1263-1277.
Article
PubMed
PMC
PDF
193. Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med 2021;385:1547-1558.
Article
PubMed
194. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, doubleblind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-690.
Article
PubMed
195. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113-1124.
Article
PubMed
196. Wei Q, Xu X, Guo L, Li J, Li L. Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 2021;12:635556.
Article
PubMed
PMC
197. Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology 2021;160:219-231 e1.
Article
PubMed
198. Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, et al. Pegbelfermin (BMS986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 2019;392:2705-2717.
Article
PubMed
199. Harrison SA, Ruane PJ, Freilich BL, Neff G, Patil R, Behling CA, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med 2021;27:1262-1271.
Article
PubMed
PDF
200. Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, Aggarwal S, et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med 2021;27:1836-1848.
Article
PubMed
PDF
201. Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, FloresFigueroa J, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2021;27:1825-1835.
PubMed
PMC
PDF
202. Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2019;394:2012-2024.
Article
PubMed
203. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology 2020;71:495-509.
Article
PubMed
PDF
204. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.
Article
PubMed
PMC
205. Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 2020;73:26-39.
PubMed
206. Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed nonalcoholic steatohepatitis and type 2 diabetes. Nat Commun 2021;12:5503.
Article
PubMed
PMC
PDF
207. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebocontrolled trial. Lancet 2015;385:956-965.
Article
PubMed
208. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:574-582 e1.
Article
PubMed
209. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019;394:2184-2196.
PubMed
210. Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol 2020;72:816-827.
Article
PubMed
211. Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol 2020;72:885-895.
Article
PubMed
212. Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 2018;67:1754-1767.
Article
PubMed
PDF
213. Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology 2020;72:892-905.
Article
PubMed
PDF
214. Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 2020;158:1334-1345 e5.
Article
PubMed
215. Dufour JF, Caussy C, Loomba R. Combination therapy for nonalcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-1884.
Article
PubMed
PMC
216. Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 2021;73:625-643.
Article
PubMed
PDF
217. Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol 2022;77:607-618.
Article
PubMed

Figure & Data

References

Citations

Citations to this article as recorded by

Therapeutic Potential of Alginate-Pectin-Chitosan Encapsulated Pediococcus acidilactici Against Bile Duct Ligation-Induced Hepatic Fibrosis in Rats
Sahar Ahmadi Asouri, Mitra Motallebi, Merat Karimi, Maryam Akhavan Taheri, Esmat Aghadavod, Mahla Qanbari, Hamed Mirzaei, Siavash Amiri, Mohammad Esmaeil Shahaboddin
Probiotics and Antimicrobial Proteins.2026; 18(2): 1837. CrossRef
Alginate oligosaccharides prevent and treat obesity by promoting brown fat thermogenesis rather than regulating gut microbiota
Yuncong Xu, Jun Jiang, Tao Li, Qiaojuan Yan, Zhengqiang Jiang, Shaoqing Yang
Journal of Advanced Research.2026; 85: 1. CrossRef
Interactions between hepatic stellate cells and immune cells: Implications for liver fibrosis
Deyu Xie, Yihui Huang, Yitian Yu, Weikai Jin, Xiangting Zhang, Fujun Yu
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026; 1872(1): 168062. CrossRef
Identification of the differential and synergic lipotoxic patterns of oleic acid, palmitic acid, and their mixture in 3D HepG2/C3A tissue using liver‐on‐chip technology
Lisa Morisseau, Valérie Pawlowski, Valérie Plaisance, Mathilde Lucas, Cécile Legallais, Yasuyuki Sakai, Amar Abderrahmani, Rachid Jellali, Eric Leclerc
Biotechnology Progress.2026;[Epub] CrossRef
Machine perfusion serves as a therapeutic platform for immunomodulatory remodeling in liver grafts from donation after circulatory death
Qing Ouyang, Jian-Xiong Chen, Bao Zhang, Yu-Jian Zheng, Shao-Ping Wang, Feng Huo
Hepatobiliary & Pancreatic Diseases International.2026; 25(3): 262. CrossRef
Orphan drug uttroside B impedes MASH progression and HCC development in experimental models
Tennyson P. Rayginia, Chenicheri K. Keerthana, Sreekumar U. Aiswarya, Sadiq C. Shifana, S. Jannet, Sanjay Suresh Varma, P. Maria Joy, Mundanattu Swetha, Shirly James, J.S. Aparna, Yadu Vijayan, Archana Payickattu Retnakumary, Lekshmi R. Nath, Kalishwarala
JHEP Reports.2026; 8(2): 101626. CrossRef
Bisphenol S promotes hepatic fibrosis through macrophage polarization- and autophagy-mediated activation of hepatic stellate cells
Yang Yang, Jingyu Qin, Meiping Guo, Yue Wang, Shuhui Wei, Xiaona Zhang
Toxicology and Applied Pharmacology.2026; 506: 117635. CrossRef
Hyperoside attenuates NASH-associated liver fibrosis by modulating Flot2/TLR4 signaling and pyroptosis
Peng Huang, Yunling Zhu, Zhiling Li, Kaixuan Zeng, Lang Qin, Jianguo Hu, Tingying Zhang, Li Zhang, Taoli Liu, Jian Qin
International Immunopharmacology.2026; 169: 116007. CrossRef
A comprehensive review of herb-induced liver injury: Mechanisms, clinical management, and future perspectives in natural product safety
Yujian Fan, Xiaokai Guo, Caibin Zhang, Tianyang Huang, Hsien-Da Huang, Yisheng He
Phytomedicine.2026; 150: 157647. CrossRef
Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis
Hayato Kawamura, Aya Naiki‐Ito, Xiaochen Kuang, Akihiro Murakami, Masayuki Komura, Takanori Suzuki, Hiroyuki Kato, Yuko Nagayasu, Kentaro Matsuura, Kei Fujiwara, Hiromi Kataoka, Satoru Takahashi
Hepatology Research.2026; 56(4): 420. CrossRef
Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: A nationwide target trial emulation study
Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
Annals of Hepatology.2026; 31(1): 102175. CrossRef
Association of waist-to-height ratio with nonalcoholic fatty liver disease and liver fibrosis detected by vibration-controlled transient elastography: NHANES 2017-2020
Kongting Xing, Chaoying Ge, Lingli Xu, Linjian Liu
Medicine.2026; 105(1): e46675. CrossRef
Fetuin B drives metabolism-associated steatohepatitis by promoting hepatocyte pyroptosis via NLRP3/GSDMD pathway
Shi Chen, Yue Wang, Jingwen Gao, Jiaxi Lin, Lu Liu, Shiqi Zhu, Lihe Liu, Chunfang Xu, Xiaolin Liu, Manhui Zhu, Jinzhou Zhu
Experimental Cell Research.2026; 456(1): 114886. CrossRef
Effect of gentiopicroside on endogenous formaldehyde homocysteine–pathway related proteins in rats with non-alcoholic steatohepatitis
Jiaxin Chen, Huiling Zuo, Yuhang Jiao, Huanhuan Zhao, Xuan Ma, Yahui Xiao, Xiangqiong Li, Wei Zhao, Anhua Shi, Wenhui Chen
Frontiers in Pharmacology.2026;[Epub] CrossRef
Research advances on whole grains benefit on metabolic syndrome via gut homeostasis regulation
Xinru Wang, Hanying Liang, Hao Zhu, Yifang Wang, Hongzhao Sun, Lingyi Liu, Jianbo Xiao, Ning Yan, Chuang Wang, Lianliang Liu
Critical Reviews in Food Science and Nutrition.2026; 66(19): 3531. CrossRef
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement
Chu-Tian Wu, Giovanni Targher, Christopher D Byrne, Zobair M Younossi, Matthew J Armstrong, Hung N Luu, Cosmas Rinaldi A Lesmana, Vinod K Rustgi, James A Thomas, Koji Okabayashi, Jonathan Wei Jie Lee, Hashem B El-Serag, Won Kim, Hai-Jun Zhang, Amedeo Lona
Gut.2026; : gutjnl-2025-337374. CrossRef
Evaluation value of ultrasonic shear wave elastic imaging, MRI combined with ADC value in liver fibrosis degree of nonalcoholic fatty liver
Yang Liu, Fei Teng, Yan Ding, Jian Zhou, Qibo Cai, Yang Shi, Qi Liu
Journal of Radiation Research and Applied Sciences.2026; 19(1): 102135. CrossRef
RNA splicing dysregulation in hepatocellular carcinoma: Molecular mechanisms, therapeutic targets, and intervention strategies—A comprehensive review
Shuai Xiong, Lei Hu, Yun-Yang Sun, Wei Huang, Xiao-Yu Hu
Biomedicine & Pharmacotherapy.2026; 195: 119025. CrossRef
The association between triglyceride glucose-waist-to-height ratio and non-alcoholic fatty liver disease in adults aged over 60 in the United States: a cross-sectional study
Lixian Lin, Guoyan Pan, Lijun Liu, Junwei Huang
Frontiers in Public Health.2026;[Epub] CrossRef
Metabolic dysregulation reshapes the immune landscape: The gut microbiota-mTOR axis in respiratory viral infection immunity
Jiaxuan Li, Jianhua Li, Keda Chen
Molecular Therapy.2026; 34(4): 1921. CrossRef
Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH
Weiheng Wen, Zenghui Liu, Wenliang Tan, Yingzheng Tan, Wei Li, Jian Wan, Hongsai Hu, Zhengwu Jiang, Xing Tang, Jing Yang, Jiao Xiao, Xiongjin Tan, Xun Chen, Peili Wu, Yukun Li
npj Digital Medicine.2026;[Epub] CrossRef
Xanthine oxidoreductase activity in MASLD: links to lipid metabolism, oxidative stress, and inflammation
Yangyang Cen, Zhiyu Pu, Xuanxuan Zi, Shenglin Peng, Ruihan Liu, Bowen Yang, Yanna Fan, Jianjun Yang, Yi Zhao, Yannan Zhang
Frontiers in Endocrinology.2026;[Epub] CrossRef
SIRT1-mediated FABP4 destabilization attenuates fibrosis and ferroptosis in non-alcoholic fatty liver disease
Haizhou Qiu, Kunlin Chen, Yiwen Qiu, Yi Yang, Tao Wang, Wentao Wang, Li Jiang
Clinical and Experimental Medicine.2026;[Epub] CrossRef
MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review
Adela Gabriela Ştefan, Adina Mitrea, Diana Clenciu, Ionela Mihaela Vladu, Maria Magdalena Roşu, Diana Cristina Protasiewicz-Timofticiuc, Theodora Claudia Radu-Gheonea, Ion-Cristian Efrem, Anca Maria Amzolini, Beatrice Elena Vladu, Ana-Maria Efrem, Delia-V
Medicina.2026; 62(2): 325. CrossRef
Inflammation burden index as a complementary marker for the assessment of hepatic steatosis and fibrosis: evidence from NHANES 2017–2018
Shaoguang Chen, Lixiao Zhu, Yulou Jiang
Abdominal Radiology.2026; 51(9): 4343. CrossRef
Sex-Specific Basal Metabolic Rate and NAFLD Risk: The Multi-Population Observational and Mendelian Randomization Study
Chunyu Hu, Yuanling Tao, Laixi Zhang, Zhen Cheng, Li Sun, Zongtao Chen
Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1. CrossRef
Xiayuxue decoction alleviates MASH by regulating gut microbiota, bile acid metabolism, and m6A modification
Jiewen Shi, Chaoqun Zhao, Dingqi Zhang, Linzhang Zhang, Qinying Feng, Shenglan Qi, Xiaoli He, Ping Liu, Yongping Mu, Gaofeng Chen, Wenna Ma, Dan Peng, Rongshen Li, Yongli Wang, Yang Cheng, Wei Liu
Phytomedicine.2026; 154: 158023. CrossRef
FOXN3 integrates the KU70/KU80/SREBP-1 complex to regulate lipid metabolism in non-alcoholic fatty liver disease
Jiang Du, Lele Jin, Suhui Wang, Xinghong Hu, Jinjin Yu, Jingyu Yu, Qingyang Huo, Nan Wu, Xiaotian Liu, Yan Yang, Yong Zhang, Sizhou Huang, Jihong Zhou, Song Guo Zheng, Chunfu Zheng, Xinxing Zhu
Nucleic Acids Research.2026;[Epub] CrossRef
Leonurine: A Multifaceted Bioactive Alkaloid—From Pharmacological Mechanisms to Clinical Translation: A Narrative Review
Zhouyue Gu
Health Science Reports.2026;[Epub] CrossRef
Association between blood selenium level and nonalcoholic fatty liver disease among naturally menopausal women: A cross-sectional study
Chen Chen, Yitong Yu, Jiayan Hu, Gang Zheng, Junxiang Li, Chune Xie, Zhibin Wang, Xiaowei Chen, Mengyu Zheng, Chengtao Liang, Zhengdao Lin, Yao Jiao, Hao Huang, Yitong Li, Anqi Yang, Tangyou Mao
Medicine.2026; 105(11): e48008. CrossRef
Association of circadian syndrome with nonalcoholic fatty liver disease and liver fibrosis: A cross-sectional study based on NHANES 2017 to 2020.03 data
Wenzhao Guo, Sijia Li, Bingjiu Lu, Xinghai Yue, Yuhang Gao, Meng Mi, Wenting Zhao, Ran Zhao, Guanhua Lv
Medicine.2026; 105(10): e47950. CrossRef
m5C: Novel Diagnostic and Drug Repurposing Targets for Nonalcoholic Steatohepatitis
Shuxian Chen, Renquan Duan, Jingyi Qiu, Zhiyu Lei, Wei Chen, Xiumei Li, Zhenyu Gong
International Journal of Genomics.2026;[Epub] CrossRef
Auricularia auricula polysaccharide attenuates Rhizoma Dioscorea bulbifera decoction-induced hepatotoxicity by regulating the TNF-α/PI3K/AKT pathway and gut microbiota
Libo Pei, Zhiying Wang, Chao Wu, Di Zhao, Xinyu Zou, Lidan Zhang, Jianjun Zhang, Le Jia
International Journal of Biological Macromolecules.2026; 354: 151315. CrossRef
DNA hypermethylation of choline kinases drives blockage of choline-phosphatidylcholine biosynthesis: lipidomic biomarkers and epigenetic insights of hepatic steatosis induced by arsenic
Qiwen Fu, Qi Wang, Dingyi Song, Xingcheng Zhou, Hualin Chen, Shaofeng Wei, Lu Ma
BMC Medicine.2026;[Epub] CrossRef
The immunometabolic network in obesity-associated insulin resistance: a systemic multi-organ and multi-cellular perspective
Yi Zhang, Haixin Ding, Xue Zhao, Yutong Li, Pengling Ge
International Immunopharmacology.2026; 177: 116528. CrossRef
First-trimester fatty liver index and hepatic steatosis index independently predict gestational diabetes risk: a prospective cohort study
Rong Shuai, Lizhong Lin, Dongqian Yang, Yuqin Shen, Li Zhang
Frontiers in Nutrition.2026;[Epub] CrossRef
Mediating role of estimated glomerular filtration rate in the association between hyperlipidemia and estimated glucose disposal rate-related mortality: a study in hyperlipidemic individuals
Wenxuan Zhang, Liya Li, Yaping Wang, Yuxiang Cao, Chengyun Hu, Jing Wang, Bing Gao
Nutrition, Metabolism and Cardiovascular Diseases.2026; 36(8): 104713. CrossRef
Shugan Jiangzhuo Tablets mitigate non-alcoholic fatty liver disease by modulating TLR4/MyD88/NF-κB signaling pathway through gut microbiota
Sifan Lu, Shiheng Wu, Yi Liu, Yufeng Gu, Yixuan Zeng, Bingying Deng, Niren Li, Zhijie Chen, Chen Zhu
Fitoterapia.2026; 191: 107202. CrossRef
Ophiopogonin D Alleviates Nonalcoholic Steatohepatitis via Ferroptosis Through AKT1/STAT3/HIF‐1α Axis
Dong Li, Meina Shi, Zhike Fang, Xiaoqing Wang, Linshi Huang, Mingguo Dong, Andrey Elchaninov
Analytical Cellular Pathology.2026;[Epub] CrossRef
Procyanidin dimers attenuate hepatic steatosis in metabolic dysfunction-associated fatty liver disease via the PI3K/AKT/Nrf2 pathway
Fangfang Tie, Yidan Gao, Yun Wu, Qi Dong, Honglun Wang, Na Hu
Food Bioscience.2026; 80: 108946. CrossRef
Integrated transcriptomic and single cell analysis combined with artificial neural network identifies a robust gene signature for early discrimination of MASL and MASH
Guo Wu Lin, Zhi Yuan Lin, Qi Yuan Su, Li Ye, Wei Ning Xu, Shun Qiang Nong, Ru Kai Wu, Wei Jie Zhou, Qian Fang Huang
Frontiers in Immunology.2026;[Epub] CrossRef
Network Toxicology Reveals the Mechanisms of the Plasticizer Metabolite MECPP in Metabolic Diseases
Jiaqi Qiu, Chang Cheng, Biao Jiang, Diqi Yang, Hui Peng
International Journal of Molecular Sciences.2026; 27(8): 3550. CrossRef
Mechanism of Action and Research Progress of Flavonoids From Traditional Chinese Medicine to Improve Metabolic Liver Disease
Xuehui Tao, Jianing Liu, Fangtong Li, Wenyi Gao, Haoming Luo, Kangyu Wang
Phytotherapy Research.2026; 40(6): 3478. CrossRef
Role of miRNA signalling in the pathogenesis of MASLD
Shi-Lin Cheng, Jun Hao, Hong-Yan Qin
Frontiers in Pharmacology.2026;[Epub] CrossRef
Association Between Thyroid Hormone Sensitivity Indicators and Controlled Attenuation Parameter (CAP) Values in Euthyroid Adults with Overweight/Obesity
Yifang Zhang, Cuiping Bao, Lingling Liu, Renjiao Liu, Xincheng Wang, Xiaoxuan Guo, Chunjun Li
Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1. CrossRef
Artemisia scoparia extract inhibits oxidative stress and ferroptosis to ameliorate MASH through AGE-RAGE and JAK1-STAT3 signaling
Linlin Wang, Yu Miao, Hailong Wang, Hamulati Hasimu, Tengfei Ji, Hua Huang, Guanhua Du, Haji Akber Aisa, Xuelei Xin
Frontiers in Pharmacology.2026;[Epub] CrossRef
SEC62 at mitochondria-associated membranes drives MASH progression by suppressing ATAD3B-mediated mitochondrial quality control
Junchao Lin, Tong Wu, Chen Wang, Wei Zhou, Yutong Liu, Gang Yang, He Zhou, Jingyan Luo, Zhenzhen Fan, Yu Da, Jie He, Bing Xu, Mingzhuo Jiang, Daiming Fan, Kaichun Wu, Jie Liang
Metabolism.2026; 180: 156623. CrossRef
Electroacupuncture in the treatment of non-alcoholic fatty liver disease: mechanistic insights and therapeutic potential
Yi Wang, Lai Zhang
Frontiers in Medicine.2026;[Epub] CrossRef
Modulating hepatic stellate cell senescence: A promising therapeutic strategy for liver fibrosis
Muthusethupathi Sharmila, Karthik Shree Harini, Devaraj Ezhilarasan
Hepatobiliary & Pancreatic Diseases International.2026; 25(4): 382. CrossRef
Research Progress on Nanoformulations Based on Active Components from Traditional Chinese Medicine for MASLD
Zi-Xiu Gou, Ning-Wei Li, Jun-Yi Yao, Yun-Liang Wang
International Journal of Nanomedicine.2026; Volume 21: 1. CrossRef
Lipid dysregulation in chronic diseases: systems biology and omics perspectives
Debashrita Majumder, Debasmita Bhattacharya, Harjot Singh Gill, Mithul Rajeev, Shubham Sharma, Shashi Prakash Dwivedi, Moupriya Nag, Dibyajit Lahiri
Xenobiotica.2026; 56(6): 534. CrossRef
Systematic characterization of active components and therapeutic mechanisms of Chaihu Guizhi Ganjiang Decoction in metabolic dysfunction-associated steatohepatitis
Hao Wu, Tengteng Wang, Shengnan Cai, Yun Qiao, Jie Liu, Yueting Li, Hongbin Xiao
Journal of Pharmaceutical and Biomedical Analysis.2026; 279: 117571. CrossRef
Metabolic and immunoinflammatory features of pancreatic steatosis in patients with metabolic dysfunction-associated steatotic liver disease under martial law
V.I. Didenko, G.I. Bocharov, O.M. Tatarchuk, S.L. Melanich, V.B. Yagmur
GASTROENTEROLOGY.2026; 60(2): 75. CrossRef
The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis
Jiang Yu, Yong Peng
Frontiers in Medicine.2026;[Epub] CrossRef
Resveratrol’s hepatic symphony: conducting a multi-stage intervention in liver cancer’s progression
Cui Guo, Fang Cao, Ling Zhou, Guijun Guo, Shaoyuan Zheng, Ruixue Xia, Qinghua Zou
Chinese Journal of Natural Medicines.2026; 24(6): 659. CrossRef
Metabolic reprogramming and epigenetic memory of hepatic stellate cells in MASLD progression
Zi-Ying Deng, Miao-Ling Huang, Xu-You Liu
World Chinese Journal of Digestology.2026; 34(4): 295. CrossRef
Proteomic Signatures of Ectopic Fat Distribution: Tissue‐Specific Drivers and Clinical Implications
Bing Zhang, Fen Yang, Xingji Lian, Jie He, Shuijin Huang, Mingjuan Fan, Yin Liang, Jiaqiang Huang, LongYan Yin, Hong Wang
Med Research.2026;[Epub] CrossRef
Calcium imbalance drives organelle network collapse and immune remodeling: novel pathogenic mechanisms in MASLD progression
Senping Xu, Ziyang Jiang, Qing Zhang, Jiawei Guo
Frontiers in Immunology.2026;[Epub] CrossRef
ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic repurposing framework target for metabolic dysfunction-associated steatohepatitis patients
Guiying Zeng, Qi Zhao, Li Jiang, Dongmei Xie, Lin Du, Mei Yang, Mei Luo, Qian Wang
Frontiers in Medicine.2026;[Epub] CrossRef
Hepatoprotective effects of the branched-chain fatty acids 12-methylmyristic and 13-methylmyristic against palmitate-induced lipotoxicity
Sara Rico-Chazarra, Carmen García-Melgares, Inmaculada Ros-Madrid, María A. Martínez-Sánchez, Lidia Sánchez-Alcoholado, Alba Oliva-Bolarín, Virginia E. Fernández-Ruiz, Mercedes Ferrer-Gómez, Antonio J. Ruiz-Alcaraz, Carlos M. Martínez, Adriana Mika, María
Biomedicine & Pharmacotherapy.2026; 201: 119687. CrossRef
Natural Alkaloids Against Liver Injury: Mechanistic Insights and Multi-Target Therapeutic Potential
Yating Xiao, Zhirui Tian, Jie Cui, Xia Yang, Dong Wang, Yangyang Cai, Qian Wu, Yaxin Jin, Hua Chen, Kai Ji
Biomolecules.2026; 16(6): 815. CrossRef
Associations of C‐Reactive Protein–Triglyceride–Glucose Index With the Incidence and Progression of Cardiometabolic Multimorbidity in Middle‐Aged and Older Chinese Individuals: A Prospective Cohort Study From CHARLS
Zhengfeng Wu, Honghong Zhang, Yajun Zheng, Haijing Zhao, Jie Liu, Yuhan Ma, Yuqi Liu
iLABMED.2026; 4(2): 65. CrossRef
Microbiota-fibroblasts interactions in multi-organ fibrosis
Caiyu Qi, Zhen Lin, Yuyang Gan, Peirong Liang, Lu Chen, Yuxuan Luo, Evan Sweren, Martin P. Alphonse, Lan Yang, Luis A. Garza, Gaofeng Wang
Microbiological Research.2026; 311: 128602. CrossRef
Lactylation in metabolic dysfunction-associated steatotic liver disease: epigenetic regulatory mechanisms and potential therapeutic strategies
Ya-qi Guo, Dan-jie Li, Chen-xi Jia, Pan-pan Hou, Chun-jie Yang, Yu-ting Xi, Xing Liu, Peng Li, Chang-zheng Li, Qian-qian Niu
Biochemical Pharmacology.2026; 251: 118193. CrossRef
Hepatic lipid accumulation induced by mono-(2-ethylhexyl) phthalate and potential ERBB2-associated inflammatory signaling in NAFLD
Caiqi Huang, Mingzhu Yin, Huimin Liu, Wenwu Jia, Lingchuan Niu, Jia Ming
Frontiers in Pharmacology.2026;[Epub] CrossRef
Short-Chain Fatty Acids: Bridging Gut Microbiota and Systemic Aging—Mechanisms, Interventions, and Current Challenges
Pengpeng Xie, Yaoye Pei, Luyun Xu, Yuanhao Shan, Xiamin Cao
Metabolites.2026; 16(7): 438. CrossRef
Mitochondrial Dysfunction in Metabolic-Syndrome-Related MASLD/MASH: Metabolic Mechanisms and Therapeutic Perspectives
Jin Jin, Yang Cheng
Metabolites.2026; 16(7): 489. CrossRef
Exploring the therapeutic potential of mitochondrial mechanism in metabolic dysfunction associated steatotic liver disease
Karthika Selvam, Shalinipriya Muthulakshmi Chinnaswamy, Sathish Jawahar, Venkatesh Gunasekaran
Egyptian Liver Journal.2026;[Epub] CrossRef
Routine biochemical indices for hepatometabolic stratification across the dysglycaemia spectrum: insulin resistance, fibrosis scores, and machine-learning integration
Pedro Villafruela-Rodríguez-Manzaneque, Jordi Tortosa-Carreres, Antonio Sierra-Rivera, Manuela Morales-Garcés, Laura Sahuquillo-Frias, Goitzane Marcaida-Benito
Advances in Laboratory Medicine / Avances en Medicina de Laboratorio.2026;[Epub] CrossRef
Clinical outcomes of lean metabolic dysfunction-associated steatotic liver disease by phenotypic subtypes
Chia-Chih Kuo, Chi-Hsing Chen, Hsing-Tao Kuo, Chih-Cheng Lai
Journal of Gastroenterology.2026;[Epub] CrossRef
Adipose tissue macrophages in metabolic inflammation and disease: Insights from single-cell and multi-omics studies
Qining Huang, Jingwen Tang, Xiaozheng Shu, Zhaoliang Su, Yu Tian
Cytokine.2026; 205: 157192. CrossRef
Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis
Daoping Wang, Yu Mou, Xuemei Wu, Hongji Wang, Qianjun Wang, Qing Rao, Enming Hu, Qing Li, Xiuyan Zheng, Lei Huang
Frontiers in Pharmacology.2026;[Epub] CrossRef
Microplastics and Nanoplastics as Potential Metabolic Disruptors: Implications for Insulin Resistance and Type 2 Diabetes
Umberto Cornelli, Claudio Casella
Toxics.2026; 14(7): 634. CrossRef
Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease
Sirui Zhu, Fangkun Yang, Haoxuan Lu, Jun Jiang, Wenming He
Frontiers in Cardiovascular Medicine.2026;[Epub] CrossRef
SIRT Family: Biological Functions and Therapeutic Targets
Jia‐Yi Wang, Feng‐Li Jiang, Fang‐Yuan Zhang, Dong‐Hui Huang, Xiao‐Ying Li, Song Gao, Hua You, Qi‐Jun Wu, Huan‐Huan Chen, Ting‐Ting Gong
MedComm.2026;[Epub] CrossRef
Refinement of Structural Alerts for Hepatic Steatosis
Anish Gomatam, James W. Firman, Georgios Chrysochoou, Larissa Camila Ribeiro de Souza, Steven J. Enoch, Judith C. Madden, Mark T. D. Cronin
Chemical Research in Toxicology.2026;[Epub] CrossRef
Exploring the Mechanism of Polysaccharide of Moutan Cortex in Treating Non-Alcoholic Steatohepatitis Based on Network Pharmacology, Molecular Docking, and Experimental Verification
家骏罗
Advances in Clinical Medicine.2026; 16(07): 1600. CrossRef
Clinical application of cluster analysis in patients with newly diagnosed type 2 diabetes
Yazhi Wang, Hui Chen
Hormones.2025; 24(1): 109. CrossRef
Diosgenin attenuates nonalcoholic fatty liver disease through mTOR-mediated inhibition of lipid accumulation and inflammation
Guoliang Yin, Hongyi Liang, Yiran Cheng, Suwen Chen, Xin Zhang, Decheng Meng, Wenfei Yu, Hongshuai Liu, Chaoyuan Song, Fengxia Zhang
Chemico-Biological Interactions.2025; 405: 111306. CrossRef
Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD
Haili Wang, Zhenqiu Liu, Hong Fan, Chengnan Guo, Xin Zhang, Yi Li, Suzhen Zhao, Luojia Dai, Ming Zhao, Tiejun Zhang
Journal of Gastroenterology.2025; 60(3): 306. CrossRef
Curcumol ameliorates alcohol and high-fat diet-induced fatty liver disease via modulation of the Ceruloplasmin/iron overload/mtDNA signaling pathway
Tingting Ding, Wanqing Shen, Wenhui Tao, Junlu Peng, Meijun Pan, Xiaoyu Qi, Wanyu Feng, Na Wei, Shuguo Zheng, Huanhuan Jin
The Journal of Nutritional Biochemistry.2025; 136: 109807. CrossRef
Aqueous extract of Cornus officinalis alleviate NAFLD via protecting hepatocytes proliferation through regulation of the tricarboxylic acid cycle
Binjie Liu, Ting Shao, Dandan Xiao, Shujie Yang, Weijie Lin, Lizhu Sun, Weiqin Zhang, Meiqing Luo, Jinlan Zhao, Lei Yang, Shasha Bai, Di Deng, Caiyan Wang, Shaogui Wang, Rong Zhang, Zhongqiu Liu, Lin An
Journal of Ethnopharmacology.2025; 341: 119330. CrossRef
SFAs facilitates ceramide’s de novo synthesis via TLR4 and intensifies hepatocyte lipotoxicity
Yuchao Zou, Lulu Tian, Liuhua Pei, Jie Hao, Tianhang Chen, Jiayu Qi, Jiannan Qiu, Yinuo Xu, Xiaokai Hu, Lin Chen, Xiaobing Dou
International Immunopharmacology.2025; 147: 114020. CrossRef
Cepharanthine relieves nonalcoholic steatohepatitis through inhibiting STAT1/CXCL10 axis-mediated lipogenesis and inflammatory responses
Pan Li, Ruoyu Zhang, Pingping Hu, Tingting Wang, Jianwei Wang
Journal of Ethnopharmacology.2025; 341: 119358. CrossRef
Gut microbiota of patients insusceptible to olanzapine-induced fatty liver disease relieves hepatic steatosis in rats
Qian Wu, Jing Wang, Chuyue Tu, Peiru Chen, Yahui Deng, Lixiu Yu, Xiaojin Xu, Xiangming Fang, Weiyong Li
American Journal of Physiology-Gastrointestinal and Liver Physiology.2025; 328(2): G110. CrossRef
High-fat/high-sucrose diet-induced renal changes in obese diabetic mice: a comparison with db/db and KK-Ay mice
Chika OKI, Kinuko UNO, Tomohiko SASASE, Takahiro TSUTSUI, Keita SEKIGUCHI, Ayane YAMAGUCHI, Kouhei MANDAI, Masami SHINOHARA, Miki SUGIMOTO, Tatsuya MAEKAWA, Katsuhiro MIYAJIMA, Takeshi OHTA
Journal of Veterinary Medical Science.2025; 87(2): 138. CrossRef
Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease
Weifeng He, Lingfeng Yan, Dongxue Hu, Jianlei Hao, Yih‐Cherng Liou, Gaoxing Luo
MedComm.2025;[Epub] CrossRef
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
Yuri Cho, Dae Won Jun
Clinical and Molecular Hepatology.2025; 31(1): e103. CrossRef
Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China
Di Shen, Xintian Cai, Junli Hu, Shuaiwei Song, Qing Zhu, Huimin Ma, Yingying Zhang, Rui Ma, Pan Zhou, Wenbo Yang, Jing Hong, Delian Zhang, Nanfang Li
Journal of Inflammation Research.2025; Volume 18: 1623. CrossRef
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Wanying Geng, Wanying Liao, Xinyuan Cao, Yingyun Yang
Biomedicines.2025; 13(2): 393. CrossRef
Feasibility of Serum Galectin-1 as a Diagnostic Biomarker for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study on a Segment of the Chinese Population Using Convenience Sampling
Ting Zeng, Fang Li, Min Yang, Yao Wu, Wei Cui, Huaming Mou, Xiaohe Luo
Biomedicines.2025; 13(2): 425. CrossRef
Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies
Maria V. Bourganou, Maria Eleni Chondrogianni, Ioannis Kyrou, Christina-Maria Flessa, Antonios Chatzigeorgiou, Evangelos Oikonomou, Vaia Lambadiari, Harpal S. Randeva, Eva Kassi
International Journal of Molecular Sciences.2025; 26(4): 1589. CrossRef
Traditional Mongolian Medicine Qiqirigan-8 alleviates non-alcoholic fatty liver disease via restoring gut microbiota and metabolism
Dandan Yang, Wuyunsiqin, YanNiu, Hashentuya, Tana, Anna, Mingxing Ma, Wenhui Zhao, Menggenduxi, Minjie Wang
Frontiers in Microbiology.2025;[Epub] CrossRef
Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
European Journal of Gastroenterology & Hepatology.2025; 37(5): 652. CrossRef
Intestinal Bacterial Dysbiosis and Liver Fibrosis in Mice Through Gut‐Liver Axis and NLRP3 Inflammatory Pathway Caused by Fine Particulate Matter
Pengfei Fu, Mei Zhang, Lirong Bai, Shanshan Chen, Wenqi Chen, Zhiping Li, Jianwei Yue, Chuan Dong, Ruijin Li
Journal of Applied Toxicology.2025; 45(6): 1030. CrossRef
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo
International Journal of Molecular Sciences.2025; 26(4): 1778. CrossRef
Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis
Xingyu Fan, Yueyue Wang, Yue Wang, Hao Duan, Yijun Du, Tianrong Pan, Xing Zhong
BMC Pharmacology and Toxicology.2025;[Epub] CrossRef
TSH-stimulated hepatocyte exosomes modulate liver-adipose triglyceride accumulation via the TGF-β1/ATGL axis in mice
Shizhan Ma, Yayun Wang, Shuteng Fan, Wanli Jiang, Mingliang Sun, Mengzhe Jing, Wenkai Bi, Meng Zhou, Dongming Wu
Lipids in Health and Disease.2025;[Epub] CrossRef
Metabolic-associated fatty liver disease in children: a modern view of the pathogenesis, clinical features, methods of diagnosis and treatment
M. Yu. Komissarova, R. S. Maltsev, A. M. Filin, M. M. Alimov, N. V. Evdokimova, V. P. Novikova
Experimental and Clinical Gastroenterology.2025; (9): 75. CrossRef
The correlation between the polymorphism of lysolecithin acyltransferase (MBOAT7) rs641738 and liver fibrosis
Yuxia Yang, Xiang Chen, Huiqin Zhang, Gang Yang, Xiaoyun Zhu, Xiujing Si, Feilong Chen, Yan Zhao, Feng Jin, Juanjuan Lu
Personalized Medicine.2025; 22(2): 113. CrossRef
High sensitivity C-reactive protein implicates heterogeneous metabolic phenotypes and severity in metabolic dysfunction associated-steatotic liver disease
Hao Wang, Junzhao Ye, Youpeng Chen, Yanhong Sun, Xiaorong Gong, Hong Deng, Zhiyong Dong, Lishu Xu, Xin Li, Bihui Zhong
BMC Gastroenterology.2025;[Epub] CrossRef
Correlation between 6PPD-Q and immune along with metabolic dysregulation induced liver lesions in outdoor workers
Zhihao Qin, Yan Li, Yanlan Qin, Zhongli Chen, Jinsong Guo, Fang Fang, Andreas Schäffer, Henner Hollert, Ying Shao
Environment International.2025; 199: 109455. CrossRef
Rhizoma Atractylodis Macrocephalae reduces HFD-induced MAFLD in mice through activated AMPK-mediated inhibition of fatty acid synthesis
Ke Zheng, Ruishuo Zhang, Yijing Xin, Yuge Zhou, Jiacheng Lin, Weifan Huang, Fang Wang, Liu Yang, Xuehua Sun, Xiaoni Kong
Liver Research.2025; 9(2): 157. CrossRef
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
Clinical and Molecular Hepatology.2025; 31(2): e186. CrossRef
The relationship between dietary sodium intake and all-cause mortality in patients with non-alcoholic fatty liver disease: a cohort study from NHANES 2003–2018
Jiajun Li, Sile Wan, Xianyu Dai, Yifeng Cui, Zhaoyang Lu
Frontiers in Nutrition.2025;[Epub] CrossRef
Linghe granules reduces hepatic lipid accumulation in Non-alcoholic fatty liver disease through regulating lipid metabolism and redox balance
Yuting Hu, Ni'ao Li, Rumian Zhang, Jia Wang, Dongdong Fang, Qianmei Zhou, Hua Zhang, Hong Cai, Yiyu Lu
Phytomedicine.2025; 141: 156654. CrossRef
Health benefits of medicinal plant natural products via microbiota-mediated different gut axes
Xiang Li, Yufan Liu, Ning Liu, Hanning Wu, Kexin Cong, Linnan Duan, Tianli Chen, Jie Zhang
Pharmacological Research.2025; 215: 107730. CrossRef
Exposure to submicroplastics promotes the progression of nonalcoholic fatty liver disease in ApoE-deficient mice
Qingwen Li, Xuan Niu, Yuli Cai, Lili Li, Zhongyuan Xia
Toxicology.2025; 515: 154137. CrossRef
MICROBIOCENOSIS DISORDERS PROVOKE OXIDATIVE STRESS AS A SIGNIFICANT PATHOGENETIC FACTOR IN NON-ALCOHOLIC STEATOHEPATITIS COMBINED WITH ISCHEMIC HEART DISEASE
I. M. Skrypnyk, E. V. Ohanisyan, G. S. Maslova, K. S. Neporada, O. A. Shaposhnyk, N. P. Prykhodko
World of Medicine and Biology.2025; 21(91): 101. CrossRef
Machine learning-based integration reveals reliable biomarkers and potential mechanisms of NASH progression to fibrosis
Jiahui Feng, Zheng Gong, Jialing Yang, Yuting Mo, Fengqian Song
Scientific Reports.2025;[Epub] CrossRef
Unlocking the potential of atractylenolide II: Mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay
Ming Gu, Zhiwei Chen, Yujun Chen, Yiping Li, Hongqing Wang, Ya-ru Feng, Peiyong Zheng, Cheng Huang
Journal of Pharmaceutical Analysis.2025; 15(12): 101318. CrossRef
Multiple machine learning algorithms identify 13 types of cell death-critical genes in large and multiple non-alcoholic steatohepatitis cohorts
Renao Jiang, Longfei Dai, Xinjian Xu, Zhen Zhang
Lipids in Health and Disease.2025;[Epub] CrossRef
Thyroid-Stimulating Hormone: An Important Target for the Prevention of Nonalcoholic Fatty Liver Disease
Z Wang, H Wang, H Sun
Physiological Research.2025; : 175. CrossRef
Bisphenols exposure and non-alcoholic fatty liver disease: from environmental trigger to molecular pathogenesis
Chang-Lei Li, Zhi-Yuan Yao, Yin-Feng Zhang, Xiao-Tong Cui, Ao Sun, Jing-Yu Cao, Zu-Sen Wang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Dietary vitamin K intake associates with reduced all-cause mortality in non-alcoholic fatty liver disease patients
Yu Huang, Xianfeng Zhu, Liang Han, Hulan Hu
Scientific Reports.2025;[Epub] CrossRef
Plasma Hepatic Transaminases and Incidence of Metabolic Syndrome Before Midlife in Military Adults: A CHIEF Cohort Study
Fang-Chen Liu, Kai-Wen Chen, Kun-Zhe Tsai, Chen-Chih Chu, Yen-Chen Lin, Yun-Chen Chang, Gen-Min Lin
Endocrine, Metabolic & Immune Disorders - Drug Targets.2025; 25(7): 582. CrossRef
ANGPTL4-the Link Binding Lipid Metabolism and Inflammation
Yueqi Zhang, Jingwen liang, Zhi Li, Yuyue Zuo, Lei Dai
Current Medicinal Chemistry.2025; 32(15): 2931. CrossRef
Glycyrrhizic acid mitigates hepatocyte steatosis and inflammation through ACE2 stabilization via dual modulation of AMPK activation and MDM2 inhibition
Longyue Zhou, Yun Yi, Bingqi Lin, Zhenwen Qiu, Chunxia Wang, Yuhao Li
European Journal of Pharmacology.2025; 1002: 177817. CrossRef
Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives
Zhiqing Zhang, Hong Yang, Fei Han, Peng Guo
Current Issues in Molecular Biology.2025; 47(6): 464. CrossRef
Non-esterified fatty acids disrupt hepatic lipid metabolism and mitochondrial function via TLR4/MyD88/IRAK2 signaling in bovine hepatocytes
Yongqiang Wen, Yazhou Wang, Juan J. Loor, Chenxu Zhao, Jianguo Wang
The Journal of Steroid Biochemistry and Molecular Biology.2025; 253: 106813. CrossRef
КЛІНІКО-МОРФОЛОГІЧНІ АСПЕКТИ ПЕРВИННОГО НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТУ ЗА НАЯВНОСТІ КОМОРБІДНОЇ ПАТОЛОГІЇ ЖОВЧНОГО МІХУРА
О. Ю. Фофанова, В. В. Феденько, З. Я. Гурик, Е. О. Кіндратів, І. Г. Лаб'як
Art of Medicine.2025; : 113. CrossRef
A new insight: crosstalk between neutrophil extracellular traps and the gut-liver axis for nonalcoholic fatty liver disease
Jinping Yin, Yanli Zhu, Rongrong Liu, Weixin Wang, Zhicheng Wang, Jianfeng Wang
Frontiers in Immunology.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease: mechanisms, oxidative stress, and the therapeutic potential of garcinol and astaxanthin
Natalia Ksepka, Katarzyna Zadka, Olga Adamska, Marcin Łapiński, Michał Ławiński, Nina Strzałkowska
Animal Science Papers and Reports.2025; 43(2): 133. CrossRef
Dietary Nucleotides Mitigate Age-Related Hepatic Lipid Dysregulation and Fibrosis
Xiaoyu Guo, Chan Wei, Rui Liu, Xiujuan Wang, Xin Wu, Yong Li, Meihong Xu
Journal of Agricultural and Food Chemistry.2025; 73(30): 18706. CrossRef
COMPARISON OF NEUTROPHIL LYMPHOCYTE RATIO AND PLATELET LYMPHOCYTE RATIO WITH THE DEGREE OF HEPATOSTEATOSIS IN OVERWEIGHT CHILDREN DIAGNOSED WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Arzu Gülseren, Didem Gulcu Taskin
Kocatepe Tıp Dergisi.2025; 26(3): 207. CrossRef
Insulin resistance as a mediator of the association between obesity, high-intensity binge drinking, and liver enzyme abnormalities in young and middle-aged adults: a cross-sectional study
Jiayi Zhu, Yinglong Duan, Ying Li, Yi Zhou, Zitong Lu, Nandan Chen, Juan Luo, Xingxing Wang, Xiaoqian Dong, Andy S. K. Cheng, Yuan Liu
Frontiers in Nutrition.2025;[Epub] CrossRef
Okra polysaccharide activates PPAR-γ signaling to attenuate metabolic-associated fatty liver disease in mice
Yaojun Cai, Yanxia Jiang, Mengxia Chen, Jixiong Xu, Zhengzheng Liao
International Journal of Biological Macromolecules.2025; 321: 146449. CrossRef
Esculetin improves lipid metabolism disorders induced by a high-fat diet by regulating the P13K-AKT signaling pathway and taurocholic acid metabolism
Liyang Guo, Yongjie Zhang, Kun Wang, Shun Wang, Yecheng Yao, Weiqi Liu, Fuhua Gu, Yifan Li, Rui Li, Jichang Li, Chunli Chen
Food Research International.2025; 221: 117281. CrossRef
Taurine alleviated paraquat-induced oxidative stress and gut-liver axis damage in weaned piglets by regulating the Nrf2/Keap1 and TLR4/NF-κB signaling pathways
Chen Chen, Min Qi, Weilong Zhang, Fanxing Chen, Zhihong Sun, Weizhong Sun, Wenjie Tang, Zhenguo Yang, Xuan Zhao, Zhiru Tang
Journal of Animal Science and Biotechnology.2025;[Epub] CrossRef
Association between dietary inflammatory index and hepatic steatosis: cross-sectional evidence from the NHANES 2007–2020
Zhounan Wu, Yuhang Liang, Li Zeng, Jiayi Fang, Jinshen He
Journal of Health, Population and Nutrition.2025;[Epub] CrossRef
Brunodelphinine A alleviates non-alcoholic fatty liver disease by inhibiting oxidative stress and regulating lipid metabolism via NOX4/SIRT1/PPARs axis
Meiqi Wang, Beixuan Yang, Xin Li, Huanhuan Ma, Xia Ou, Zeren Dawa, Fangle Liu, Chenchen Zhu, Chaozhan Lin
Phytomedicine.2025; 147: 157202. CrossRef
Research advances in self-assembled peptide delivery systems for fibrosis treatment
Yanwen Zhang, Di Su, Yin Wang
Precision Medicine and Engineering.2025; 2(4): 100043. CrossRef
Protein palmitoylation: an emerging regulator of inflammatory signaling and diseases
Rong Chen, Xiaohua Tang, Ying Wang, Bo Wang, Fei Mao
Frontiers in Immunology.2025;[Epub] CrossRef
Amentoflavone as a dual-target inhibitor of IL11 signaling alleviates intervertebral disc fibrosis
Rongsheng Chen, Zhibin Chen, Yiping Chen, Boxuan Xu, Min Su, Weihong Xu
International Immunopharmacology.2025; 165: 115450. CrossRef
The frontline of metabolic dysfunction–associated steatotic liver disease: More to be discovered
Chun-Ting Ho, Wei-Yu Kao, Chien-Wei Su
Journal of the Chinese Medical Association.2025; 88(9): 660. CrossRef
Liver metabolic health and the components of metabolic syndrome in people living with HIV – do they differ from those in a ‘healthy’ population?
Michał Biały, Marcin Czarnecki, Małgorzata Inglot
HIV Research & Clinical Practice.2025;[Epub] CrossRef
The Role of ROS‐Mediated Mitochondrial Dysfunction in the Development of Malignant Melanoma
Lei Li, Zhiwei Zeng, Tengxiao Ma, Bo Hu, Muye Guo, Qiaoxing Wang
Experimental Dermatology.2025;[Epub] CrossRef
Linear ubiquitination prevents lipodystrophy and obesity-associated metabolic syndrome
Ximena Hildebrandt, Önay Veli, Armel Hyoubi, Julia Zinngrebe, Ali T. Abdallah, Julian Rodefeld, Anne Hoffmann, Liane Gardeweg, Öykü Kaya, Elena Wagner, Andreas Lindhorst, Matea Poggenberg, Yuan Wang, Joëlle Dimmler, Jutta Schillings, Pegi Koci, Francesca
Science Advances.2025;[Epub] CrossRef
Advances in essential oils for metabolic diseases
Xinxin Li, Min Tong, Huilian Cao, Xiangjuan Sun, Fenghua Zhang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Beyond inflammation: what drives the self-perpetuating cycle of fibrosis in IBD?
Yutong Wei, Zhou Zhou, Shiyu Xiao
Annals of Medicine.2025;[Epub] CrossRef
Research Progress and Prospects of Saponins in the Treatment of NAFLD: A Narrative Review
Shuang Xue, Qiao Wang, Xuan Guo, Xingtong Chen, Yunyue Zhou, Jinbiao Yang, Yukun Zhang, Wenying Niu
Molecules.2025; 30(21): 4247. CrossRef
Shugan Xiaozhi Decoction attenuates nonalcoholic steatohepatitis by modulating oxidative stress and AMPK pathway
Rong Yang, Lian Feng, Zhijian Gong, Huili Yang, Haiyan Du, Jing Chen, Meirong Qin, Ning Chen, Houshuang Huang, Ping Wang, Qibiao Wu, Yufeng Xing
BMC Complementary Medicine and Therapies.2025;[Epub] CrossRef
Analysis of factors affecting early hepatic steatosis in pediatric patients with Wilson’s disease in China: A retrospective study
Meixia Wang, Fei Wang, Zhuang Tao, Wenming Yang
Medicine.2025; 104(45): e45501. CrossRef
The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials
Ranran Kan, Siyi Wang, Xiaoyu Meng, Yaming Guo, Danpei Li, Xuefeng Yu
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Ameliorative Potential of Menstrual Blood-derived Endometrial Stem Cells in Alcohol-induced Fatty Liver Disease
Yan Jiang, Qingyang Huo, Jingwen Gao, Beilin Kou, Narazah Mohd Yusoff, Emmanuel Jairaj Moses, Juntang Lin
Current Stem Cell Research & Therapy.2025; 20(8): 869. CrossRef
Polymer-lipid hybrid nanoparticles incorporating green coffee extract: enhancing treatment for hepatic steatosis and fibrosis through metabolomic insights
Marco A. Uriostegui-Campos, Shaula A. Castro-Murrieta, Ximena I. Lopez-Cesati, Ricardo Colín-Delgado, Gabriela I. Carballo-López, Karla Cervantes-Luevano, Aldo Moreno-Ulloa, Ana B. Castro-Ceseña
RSC Advances.2025; 15(55): 46775. CrossRef
Plant-based dietary miRNAS: cross-border regulatory factors for regulating glycolipid metabolism and their nutritional intervention strategies
Yaping Liu, Xingyue Tao, Xiaoxiao Wang, Huilin Lv, Huomin Luo, Peifeng Li
Frontiers in Nutrition.2025;[Epub] CrossRef
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications
Wenhua Bai, Zheng Zhu
Frontiers in Endocrinology.2025;[Epub] CrossRef
Analysis of risk factors and correlation between the degree of hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatohepatitis
Xiaojin Yang, Desheng Xie, Yao Du, DongHong Zhang, Houji Chen, Yinghua Yuan
BMC Gastroenterology.2025;[Epub] CrossRef
The heterogeneity of monocyte-derived macrophages in MASH pathogenesis
Miao Zhang, Erzhuo Xia, Chongxiao Li, Shuoyi Ma, Fangfang Yang, Siyuan Tian, Xia Zhou, Xiaohong Zheng, Bo Li, Hui Yang, Jingbo Wang, Ying Han
Cell Communication and Signaling.2025;[Epub] CrossRef
Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD
Xinyang Yu, Shaolong Qi, Wanyue Cao, Meiqi Cheng, Wenjie Zhang, Yangfan Wang, Rujia Zheng, Gaowei Jin, Xiaomin Gao, Meixin Lu, Jiaqi Lei, Kun Peng, Xinhui Su, Qi Zhang, Guocan Yu
Science Translational Medicine.2025;[Epub] CrossRef
Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm
Alfredo Caturano, Davide Nilo, Giovanni Di Lorenzo, Maria Rocco, Giuseppina Tagliaferri, Alessia Piacevole, Mariarosaria Donnarumma, Ilaria Iadicicco, Simona Maria Moretto, Carlo Acierno, Celestino Sardu, Vincenzo Russo, Marco Alfonso Perrone, Erica Vetra
Reviews in Cardiovascular Medicine.2025;[Epub] CrossRef
Hypertension and NAFLD risk: Insights from the NHANES 2017–2018 and Mendelian randomization analyses
Mengqin Yuan, Jian He, Xue Hu, Lichao Yao, Ping Chen, Zheng Wang, Pingji Liu, Zhiyu Xiong, Yingan Jiang, Lanjuan Li
Chinese Medical Journal.2024; 137(4): 457. CrossRef
MicroRNA-582-3p knockdown alleviates non-alcoholic steatohepatitis by altering the gut microbiota composition and moderating TMBIM1
Shuo Huang, Xia Xiao, Hongman Wu, Feng Zhou, Chenchao Fu
Irish Journal of Medical Science (1971 -).2024; 193(2): 909. CrossRef
From NAFLD to MASLD: When metabolic comorbidity matters
Shan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei
Annals of Hepatology.2024; 29(2): 101281. CrossRef
Machine learning-based integration identifies the ferroptosis hub genes in nonalcoholic steatohepatitis
Longfei Dai, Wenkang Yuan, Renao Jiang, Zhicheng Zhan, Liangliang Zhang, Xinjian Xu, Yuyang Qian, Wenqi Yang, Zhen Zhang
Lipids in Health and Disease.2024;[Epub] CrossRef
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng
Alimentary Pharmacology & Therapeutics.2024; 59(7): 802. CrossRef
Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis
Lei Wang, Jieying Zhou, Jian Wang, Xiaotang Wang, Haijuan Dong, Lingzhi Zhao, Junchen Wu, Juanjuan Peng
Advanced Healthcare Materials.2024;[Epub] CrossRef
Effect of Blueberry Supplementation on a Diet-Induced Rat Model of Prediabetes—Focus on Hepatic Lipid Deposition, Endoplasmic Stress Response and Autophagy
Gonçalo Ferreira, Pedro Vieira, André Alves, Sara Nunes, Inês Preguiça, Tânia Martins-Marques, Tânia Ribeiro, Henrique Girão, Artur Figueirinha, Lígia Salgueiro, Manuela Pintado, Pedro Gomes, Sofia Viana, Flávio Reis
Nutrients.2024; 16(4): 513. CrossRef
Liver-based inter-organ communication: A disease perspective
Xin-Yan Luo, Si-Qi Ying, Yuan Cao, Yan Jin, Fang Jin, Chen-Xi Zheng, Bing-Dong Sui
Life Sciences.2024; 351: 122824. CrossRef
STUB1 increases adiponectin expression by inducing ubiquitination and degradation of NR2F2, thereby reducing hepatic stellate cell activation and alleviating non-alcoholic fatty liver disease
Zheng Mao, Jindong Zhao, Fan Cui, Zhen Li, Jinjin Cao, Jingjing Zhou, Mingliang Hou, Zengkun Qian
Tissue and Cell.2024; 88: 102345. CrossRef
The Renin–Angiotensin System and Cardiovascular–Kidney–Metabolic Syndrome: Focus on Early-Life Programming
You-Lin Tain, Chien-Ning Hsu
International Journal of Molecular Sciences.2024; 25(6): 3298. CrossRef
Dietary inflammatory index is associated with metabolic dysfunction-associated fatty liver disease among United States adults
Jing Yan, Jun Zhou, Yuanyuan Ding, Chuantao Tu
Frontiers in Nutrition.2024;[Epub] CrossRef
Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, Adriano Cressoni Araújo, Ricardo de Alvares Goulart, Marcelo Dib Bechara, Lucas Fornari Laurindo, Nahum Méndez-Sánchez, Sandra Maria Barbalho
International Journal of Molecular Sciences.2024; 25(7): 3694. CrossRef
Immunopathogenesis of liver fibrosis in steatotic liver disease
Chaerin Woo, Won-Il Jeong
Clinical and Molecular Hepatology.2024; 30(2): 299. CrossRef
Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways
Liping You, Tao Wang, Wenxuan Li, Jinghao Zhang, Chao Zheng, Yanxi Zheng, Suyin Li, Zhi Shang, Jiacheng Lin, Fang Wang, Yihan Qian, Zhijia Zhou, Xiaoni Kong, Yueqiu Gao, Xuehua Sun
Journal of Ethnopharmacology.2024; 329: 118165. CrossRef
Adherence to an antioxidant diet and lifestyle is associated with reduced risk of cardiovascular disease and mortality among adults with nonalcoholic fatty liver disease: evidence from NHANES 1999–2018
Yingzi Li, Yipin Liu
Frontiers in Nutrition.2024;[Epub] CrossRef
Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
Devaraj Ezhilarasan
Metabolism.2024; 155: 155912. CrossRef
Would Combination Be Better: Swimming Exercise and Intermittent Fasting Improve High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Obese Rats via the miR-122-5p/SREBP-1c/CPT1A Pathway
Kang Yang, Chengye Liu, Jun Shao, Lingxiang Guo, Qing Wang, Zhaoxiang Meng, Xing Jin, Xianghe Chen
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1675. CrossRef
Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
Yamei Li, Ping Qi, Si-Yuan Song, Yiping Wang, Hailian Wang, Peng Cao, Yu’e Liu, Yi Wang
Biomedicine & Pharmacotherapy.2024; 174: 116585. CrossRef
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Amedeo Lonardo
Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Role of Culinary Indian Spices in the Regulation of TGF‐β Signaling Pathway in Inflammation‐Induced Liver Cancer
Ajay Sarija Asoka, Anusha Kolikkandy, Bhagyalakshmi Nair, Adithya J. Kamath, Gautam Sethi, Lekshmi R. Nath
Molecular Nutrition & Food Research.2024;[Epub] CrossRef
Unraveling the relationship between histone methylation and nonalcoholic fatty liver disease
Li Xu, Yu-Hong Fan, Xiao-Jing Zhang, Lan Bai
World Journal of Hepatology.2024; 16(5): 703. CrossRef
Preventing High Fat Diet-Induced Obesity and Related Hepatic Steatosis by Chlorin e6-Mediated Photodynamic Therapy
Pallavi Gurung, Junmo Lim, Yong-Wan Kim
Pharmaceuticals.2024; 17(6): 729. CrossRef
Leonurine: a comprehensive review of pharmacokinetics, pharmacodynamics, and toxicology
Siyu Liu, Chen Sun, Hailin Tang, Cheng Peng, Fu Peng
Frontiers in Pharmacology.2024;[Epub] CrossRef
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic
Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef
Dual effects of Psoraleae Fructus on the liver: hepatoprotection or hepatoxicity?
Qianhui Tang, Qinwei Yu, Bin Ni, Zhenzhou Jiang, Luyong Zhang
Acupuncture and Herbal Medicine.2024; 4(2): 176. CrossRef
Changes in alanine aminotransferase and body composition and metabolic factors among individuals receiving medical health checkups
Saori Onishi, Akira Fukuda, Masahiro Matsui, Kosuke Ushiro, Tomohiro Nishikawa, Akira Asai, Soo Ki Kim, Hiroki Nishikawa
Hepatology Research.2024; 54(12): 1193. CrossRef
The use of traditional Chinese medicine in the treatment of non-alcoholic fatty liver disease: A review
Zhaolin Sun, Yuhua Wei, Yuchen Xu, Jianwei Jiao, Xiuying Duan
Pharmacological Research - Modern Chinese Medicine.2024; 12: 100475. CrossRef
A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis
Lucia M. Chávez-López, Gabriela I. Carballo-López, Karina del Carmen Lugo-Ibarra, Ana B. Castro-Ceseña
RSC Medicinal Chemistry.2024; 15(8): 2622. CrossRef
Gut microbiota changes and novel markers associated with liver steatosis in obese patients
Kh.A. Moskva, O.P. Kikhtyak, M.O. Kondratyuk, M.L. Farmaha, Ya.L. Leshchuk, S.I. Fediaieva, Ye.S. Leshchuk, T.A. Kikhtiak
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(3): 179. CrossRef
Usefulness of Body Fat and Visceral Fat Determined by Bioimpedanciometry versus Body Mass Index and Waist Circumference in Predicting Elevated Values of Different Risk Scales for Non-Alcoholic Fatty Liver Disease
María Gordito Soler, Ángel Arturo López-González, Daniela Vallejos, Emilio Martínez-Almoyna Rifá, María Teófila Vicente-Herrero, José Ignacio Ramírez-Manent
Nutrients.2024; 16(13): 2160. CrossRef
Research Progress of Porphyrin Metabolism in Fatty Liver Disease
雯郭
Advances in Clinical Medicine.2024; 14(07): 321. CrossRef
Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho
Clinical and Molecular Hepatology.2024; 30(3): 561. CrossRef
Association between SII and markers of liver injury: A cross-sectional study from the NHANES (2017–2020)
Xu-Feng Zhang, Yu-Yan Qin, Miguel Marcos
PLOS ONE.2024; 19(7): e0303398. CrossRef
Atf3-mediated metabolic reprogramming in hepatic macrophage orchestrates metabolic dysfunction–associated steatohepatitis
Shuwei Hu, Rui Li, Dongxu Gong, Pei Hu, Jitu Xu, Yingjie Ai, Xiaojie Zhao, Chencheng Hu, Minghuan Xu, Chenxi Liu, Shuyu Chen, Jie Fan, Zhonghua Zhao, Zhigang Zhang, Huijuan Wu, Yanyong Xu
Science Advances.2024;[Epub] CrossRef
Tetrahydrocurcumin ameliorates hepatic steatosis by restoring hepatocytes lipophagy through mTORC1-TFEB pathway in nonalcoholic steatohepatitis
Jiazhen Wu, Fengkun Guan, Haipiao Huang, Hanbin Chen, Yuhong Liu, Shangbin Zhang, Muxia Li, Jianping Chen
Biomedicine & Pharmacotherapy.2024; 178: 117297. CrossRef
Noncoding RNA-Mediated Epigenetic Regulation in Hepatic Stellate Cells of Liver Fibrosis
Ruoyu Gao, Jingwei Mao
Non-Coding RNA.2024; 10(4): 44. CrossRef
Tanshinone IIA Inhibits the Endoplasmic Reticulum Stress-Induced Unfolded Protein Response by Activating the PPARα/FGF21 Axis to Ameliorate Nonalcoholic Steatohepatitis
Dajin Pi, Zheng Liang, Jinyue Pan, Jianwei Zhen, Chuiyang Zheng, Wen Fan, Qingliang Song, Maoxing Pan, Qinhe Yang, Yupei Zhang
Antioxidants.2024; 13(9): 1026. CrossRef
Experimental models of fibrosis
Vadim A. Kosolapov, Roman A. Litvinov, Alexander A. Spasov
Journal of Volgograd State Medical University.2024; 21(3): 39. CrossRef
Serum follistatin like 1 in children with obesity and metabolic-associated fatty liver disease
Lujie Liu, Meng Li, Yujie Qin, Luyang Liu, Yanfeng Xiao
BMC Endocrine Disorders.2024;[Epub] CrossRef
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG
Chinese Journal of Natural Medicines.2024; 22(8): 724. CrossRef
Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus
Xiaohui Lei, HaiYan Chen, YuXin Xu, Zhuoran Yang, Lili Zhang, Cong Wang, Hu Du
BMJ Open Diabetes Research & Care.2024; 12(5): e004514. CrossRef
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fa
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clinical and Molecular Hepatology.2024; 30(4): 649. CrossRef
Advances in the understanding of the role and mechanism of action of PFKFB3‑mediated glycolysis in liver fibrosis (Review)
Qian Liu, Jiajia Li, Xin Li, Li Zhang, Shun Yao, Yongfeng Wang, Biguang Tuo, Hai Jin
International Journal of Molecular Medicine.2024;[Epub] CrossRef
КЛІНІЧНИЙ ПРОФІЛЬ ПАЦІЄНТІВ ІЗ НЕАЛКОГОЛЬНОЮ ЖИРОВОЮ ХВОРОБОЮ ПЕЧІНКИ ТА ІНСУЛІНОРЕЗИСТЕНТНІСТЮ
О. А. Козак
Здобутки клінічної і експериментальної медицини.2024; (3): 47. CrossRef
The correlation between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) with non-alcoholic fatty liver disease: an analysis of the population-based NHANES (2017–2018)
Yuhao Yang, Shengxi Li, Zhenmei An, Shuangqing Li
Frontiers in Medicine.2024;[Epub] CrossRef
Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
Han Ah Lee
The Ewha Medical Journal.2024;[Epub] CrossRef
Regulation of Inflammation, Lipid Metabolism, and Liver Fibrosis by Core Genes of M1 Macrophages in NASH
Xingyu Xu, Yaqin Dong, Jianjun Liu, Peng Zhang, Wenqi Yang, Longfei Dai
Journal of Inflammation Research.2024; Volume 17: 9975. CrossRef
Ganoderma lucidum Spore Powder Alleviates Metabolic-Associated Fatty Liver Disease by Improving Lipid Accumulation and Oxidative Stress via Autophagy
Yuxuan Zhang, Jiali Zhou, Lan Yang, Hang Xiao, Dongbo Liu, Xincong Kang
Antioxidants.2024; 13(12): 1501. CrossRef
Role of MMP-2 and MMP-9 in the Relationship between Inflammation, Fibrosis, and Apoptosis during Progression of Non-Alcoholic Fatty Liver Disease and Diagnostic Significance of Plasma Levels of Their Active Forms
Irina V. Kurbatova, Lyudmila V. Topchieva, Olga P. Dudanova, Anastasia A. Shipovskaya
Biochemistry (Moscow).2024; 89(11): 1998. CrossRef
The moderating effect of dietary fiber intake on the association between sleep pattern and liver fibrosis in metabolic dysfunction-associated steatotic liver disease: a study from NHANES
Guoqing Jia, Mengzhen Jia, Chuntao Li
BMC Gastroenterology.2024;[Epub] CrossRef
Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances
Liangtao Zhao, Haolan Tang, Zhangjun Cheng
Pharmaceuticals.2024; 17(12): 1724. CrossRef
Ultrasonographic findings in female inmates in a prison unit in the state of São Paulo, Brazil
Soraya Gomes de Amorim Andrade, Fernando Moreira de Andrade, Edward Araujo Júnior, Wagner José Gonçalves, José Mendes Aldrighi
Radiologia Brasileira.2024;[Epub] CrossRef
Neuregulin 4 as a novel adipokine in energy metabolism
Yuanbin Liu, Mingkai Chen
Frontiers in Physiology.2023;[Epub] CrossRef
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef
Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh
Frontiers in Endocrinology.2023;[Epub] CrossRef
A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation
Junya Suzuki, Kosuke Kaji, Norihisa Nishimura, Takahiro Kubo, Fumimasa Tomooka, Akihiko Shibamoto, Satoshi Iwai, Yuki Tsuji, Yukihisa Fujinaga, Koh Kitagawa, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji
Biomedicines.2023; 11(5): 1295. CrossRef
In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
Young-Sun Lee, Ekihiro Seki
Cellular and Molecular Gastroenterology and Hepatology.2023; 16(3): 355. CrossRef
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel
World Journal of Gastroenterology.2023; 29(32): 4831. CrossRef
Obeticholic acid treatment of mice to promote fertilization and reproduction
Ming Liang, Huailiang Yang, Lanyong Xu, Longqiao Cao
Zygote.2023; 31(6): 527. CrossRef
Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis
Athina Goliopoulou, Panagiotis Theofilis, Evangelos Oikonomou, Artemis Anastasiou, Panteleimon Pantelidis, Maria Ioanna Gounaridi, Georgios E. Zakynthinos, Ourania Katsarou, Eva Kassi, Vaia Lambadiari, Dimitris Tousoulis, Manolis Vavuranakis, Gerasimos Si
International Journal of Molecular Sciences.2023; 24(18): 14292. CrossRef
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef
Dietary and lifestyle oxidative balance scores are independently and jointly associated with nonalcoholic fatty liver disease: a 20 years nationally representative cross-sectional study
Yuanbin Liu, Mingkai Chen
Frontiers in Nutrition.2023;[Epub] CrossRef
Naringin ameliorates liver fibrosis in zebrafish by modulating IDO1-mediated lipid metabolism and inflammatory infiltration
Meng-chen Qin, Jun-jie Li, Yan-tao Zheng, Yun-jia Li, Yu-xue Zhang, Rou-xuan Ou, Wei-yi He, Jia-min Zhao, Su-tong Liu, Ming-hao Liu, Hai-yan Lin, Lei Gao
Food & Function.2023; 14(23): 10347. CrossRef
Association between nonalcoholic fatty liver disease and type 2 diabetes: A bidirectional two-sample mendelian randomization study
Xuetong Ni, Chao Tong, Aheyeerke Halengbieke, Tengrui Cao, Jianmin Tang, Lixin Tao, Deqiang Zheng, Yumei Han, Qiang Li, Xinghua Yang
Diabetes Research and Clinical Practice.2023; 206: 110993. CrossRef
Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Kamlesh K. Bhopale, Mukund P. Srinivasan
Livers.2023; 3(4): 597. CrossRef
Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
Ying Zhao, Yanni Zhou, Dan Wang, Ziwei Huang, Xiong Xiao, Qing Zheng, Shengfu Li, Dan Long, Li Feng
International Journal of Molecular Sciences.2023; 24(24): 17514. CrossRef
Inducible nitric oxide synthase accelerates nonalcoholic fatty liver disease progression by regulating macrophage autophagy
Guiyuan Jin, Xiaoying Yao, Dong Liu, Juan Zhang, Xiaobei Zhang, Yonghong Yang, Yanzhen Bi, Hui Zhang, Guanjun Dong, Huixin Tang, Shumin Cheng, Feng Hong, Meng Si
Immunity, Inflammation and Disease.2023;[Epub] CrossRef
Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han
Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef
Principales fonctions hépatiques
M. Maitre, C. Klein
EMC - Hépatologie.2023; 38(4): 1. CrossRef

Cite

CITE

export

Copy Download

Format
XML Download

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
bib — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

Figure

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Figure 1. Progression of hepatic steatosis to inflammation and fibrosis in liver. Both metabolic and genetic factors contribute to the formation of hepatic steatosis. Fat accumulation in hepatocytes leads to organelles dysfunction and lipotoxicity. Then, oxidative stress species or signaling molecules are transmitted through extracellular vesicles or diffusion, activating other parenchymal and non-parenchymal cells, which subsequently causes inflammatory cascades, steatohepatitis, and liver fibrosis. On the other hand, gut-derived bacterial end-products, metabolites, gut hormones, adipose tissue-derived cytokines or adipokines, and renin-angiotensin-system all contribute to the progression from steatosis to inflammation and fibrosis. SFA, saturated fatty acid; TG, triglyceride; ER, endoplastic reticulum; HH-OPN, Hedgehog-osteopontin; KC, Kupffer cell; HSC, hepatic stellate cell.

Figure 1.

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Type of drug	Mechanism of action	Drug name	Study design	Study outcome	Reference
PPAR agonist	PPAR-γ: ↑ insulin sensitivity modulates adipose tissue distribution	Pioglitazone (PPAR-γ agonist)	RCT; NASH, prediabetes/DM	↓ ALT/AST	[188]
			Pioglitazone vs. placebo	↓ Steatosis, ballooning necrosis, and inflammation	[189]
	PPAR-α: ↑ fatty acid β-oxidation			Fibrosis not improved
	PPAR-δ: anti-inflammatory		RCT; NASH	↓ ALT/GGT
			Pioglitazone vs. placebo	Histology improvement, including liver injury and fibrosis
		Pemafibrate (SPPARMα)	Phase II RCT; NAFLD and ↑ ALT	↓ ALT	[192]
			Phase II RCT; NAFLD and ↑ ALT	↓ Liver stiffness
			Pemafibrate vs. placebo	No significant change of liver fat
		Lanifibranor (Pan-PPAR agonist)	Phase IIb RCT; NASH (SAF-A ≥3)	↓ SAF-A score ≥2 points in lanifibranor 1,200 mg group	[193]
		Lanifibranor (Pan-PPAR agonist)	Lanifibranor vs. placebo	↓ SAF-A score ≥2 points in lanifibranor 1,200 mg group
GLP-1 agonist	↑ Insulin secretion	Liraglutide	Phase II RCT; NASH, obesity	↑ Resolution of NASH without worsening of fibrosis	[194]
	↓ Glucagon secretion	Liraglutide	Liraglutide vs. placebo	No difference in fibrosis improvement
	↓ Gastric emptying	Semaglutide	RCT, phase II; NASH (F1–F3 fibrosis)	↑ Resolution of NASH without worsening of fibrosis in semaglutide 0.4 mg group	[195]
	↓ Appetite	Semaglutide	Semaglutide vs. placebo	No difference in fibrosis improvement
SGLT2 inhibitor	↑ Urinary excretion of glucose	SGLT2 inhibitors	Meta-analysis of 10 RCTs; NAFLD, DM	↓ ALT/AST	[196]
SGLT2 inhibitor	↑ Urinary excretion of glucose	SGLT2 inhibitors	SGLT2 inhibitor vs. other antidiabetic drugs	↓ Liver fat content, visceral fat, and subcutaneous fat areas
FGF-19 analogue	↓ Bile acids synthesis	Aldafermin	Phase II RCT; NASH (NAS ≥4, F2–F3 fibrosis, and liver fat content ≥8%)	↓ ALT/AST	[197]
	↓ Hepatic gluconeogenesis			↓ Liver fat fraction on MRI-PDFF
	↓ DNL		Aldafermin vs. placebo
	↑ Fatty acid oxidation		Aldafermin vs. placebo
FGF-21 analogue	↓ Hepatic gluconeogenesis	Pegbelfermin	Phase IIa RCT; NASH (F1–F3 fibrosis, and liver fat content ≥10%), obesity	↓ Liver fat fraction on MRI-PDFF	[198]
	↑ Insulin sensitivity
	↑ Energy expenditure		Pegbelfermin vs. placebo
	↑ Mitochondria beta-oxidation in hepatocytes	Efruxifermin	Phase IIa RCT; NASH	↓ Liver fat fraction on MRI-PDFF	[199]
	↑ Mitochondria beta-oxidation in hepatocytes	Efruxifermin	Efruxifermin vs. placebo	↓ Liver fat fraction on MRI-PDFF
Acetyl-CoA carboxylase inhibitor	↓ DNL	PF-05221304	2 phase IIa RCTs; NAFLD/NASH	PF-05221304 monotherapy:	[200]
Acetyl-CoA carboxylase inhibitor	↑ Fatty acid oxidation	PF-05221304	PF-05221304 monotherapy vs. placebo	↓Liver fat on MRI-PDFF, but ↑ TG
Diacylglycerol acyltransferase 2 inhibitor	↓ Synthesis of fatty acids into TGs	PF-06865571	PF-05221304 and PF-06865571 co-administration vs. placebo	Co-administration therapy: ↓ liver fat and mitigated ACC inhibitormediated effect on TG
Stearoyl-CoA desaturase 1 inhibitor	↓ DNL	Aramchol	Phase IIb RCT; NASH	↓ Liver fat content in aramchol 600 mg group, but not significant	[201]
Stearoyl-CoA desaturase 1 inhibitor	↓ DNL	Aramchol	Aramchol vs. placebo
Selective thyroid hormone receptor-β agonist	↓ LDL, cholesterol, and TG	Resmetirom	Phase II RCT; NASH (F1–F3 fibrosis, and liver fat content ≥10%)	↓ Liver fat on MRI-PDFF	[202]
Selective thyroid hormone receptor-β agonist	↑ Fatty acid oxidation	Resmetirom	Resmetirom vs. placebo	↓ Liver fat on MRI-PDFF
Anti-oxidant	Anti-oxidative stress	Vitamin E	RCT; NASH, no DM	↓ ALT/AST for both vitamin E and pioglitazone groups	[204]
			Vitamin E vs. pioglitazone vs. placebo	NASH improvement in vitamin E group, but not in pioglitazone group
			Vitamin E vs. pioglitazone vs. placebo	Fibrosis not improved in vitamin E and pioglitazone groups
Bile acid analogue	Anti-inflammation	Berberine ursodeoxycholate	Phase II RCT; NAFLD, DM	↓ Liver fat content on MRI-PDFF	[206]
	Anti-inflammation	Berberine ursodeoxycholate	Berberine ursodeoxycholate vs. placebo	↓ Liver fat content on MRI-PDFF
	↓ DNL	Obeticholic acid (FXR agonist)	Phase III RCT; NASH (NAS ≥4, F2–F3 fibrosis or F1 with ≥1 accompanying comorbidity)	↓ Fibrosis	[209]
	↑ Fatty acid β-oxidation			No significant resolution of NASH
	↑ Cholesterol excretion		Obeticholic acid vs. placebo	No significant resolution of NASH

Agent	Mechanism	Patient	Outcome	Status	ClinicalTrials.gov identifier
Lanifibranor	Pan-PPAR agonist	NASH with stage 2–3 fibrosis without cirrhosis	NASH resolution; fibrosis improvement; liver-related events	Recruiting	NCT04849728
Semaglutide	GLP-1 agonist	NASH with stage 2–3 fibrosis	NASH resolution; fibrosis improvement; liver-related events	Recruiting	NCT04822181
Dapagliflozin	SGLT2 inhibitor	NASH and type 2 DM without cirrhosis	Histology improvement	Recruiting	NCT03723252
Resmetirom	Selective thyroid hormone receptor-β agonist	NASH without cirrhosis	NASH resolution; liver-related events	Recruiting	NCT03900429
Aramchol	Stearoyl-CoA desaturase 1 inhibitor	NASH with stage 2–3 fibrosis without cirrhosis; type 2 DM or prediabetes	NASH resolution; fibrosis improvement	Recruiting	NCT04104321
Belapectin	Galectin-3 inhibitor	NASH cirrhosis without esophageal or gastric varices	Newly developed esophageal varices	Recruiting	NCT04365868
Oltipraz	Liver X receptor alpha-inhibitor	NAFLD without cirrhosis	Liver fat	Recruiting	NCT04142749

Table 1. Promising pharmacological therapies for NAFLD or NASH

Table 2. Ongoing phase III clinical trials of pharmacological agents in patients with NAFLD or NASH

Articles

Page Path

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Full Article

ABSTRACT

INTRODUCTION

PATHOGENESIS OF NASH

Diet

Physical inactivity

Insulin resistance

Genetic factors

Epigenetic factor

Endoplasmic reticulum (ER) stress

Mitochondrial dysfunction

Lysosomal dysfunction

Oxidative stress and apoptosis

DEVELOPMENT OF NASH FIBROSIS

ORGAN-ORGAN INTERACTION LEADING TO PROGRESSION OF NASH AND ITS FIBROSIS

PROGRESSION OF NASH TO HCC

TREATMENT FOR NASH

Lifestyle modification

Surgery

Endoscopic therapy

Fecal microbiota transplantation

Agents targeting hepatic fat accumulation

Agents targeting oxidative stress, inflammation, and apoptosis

Agents targeting gut-liver axis

Agents targeting liver fibrosis

Combination therapy

PERSPECTIVES

ACKNOWLEDGMENTS

FOOTNOTES

Abbreviations

REFERENCES

Figure & Data

References

Citations

CITE

Download Citation

Format:

Include:

Figure

Related articles

Figure 1.

Table 1.

Table 2.

ABOUT

BROWSE ARTICLES

FOR CONTRIBUTORS